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SUMMARY
Pure samples of gentamicin ^la' ^2 seven minor components 
were isolated from a commercial mixture of gentamicin sulphate using 
column chromatography on TLC grade silica gel. A preparative HPLC 
method based on this separation is also described. Sufficient quanti­
ties of the minor components were isolated for spectroscopic 
examination. With one exception they were less biologically active 
against Bacillus pumilus than the 3 major components.
Quantitation of gentamicin in commercial samples by spectro- 
fluorimetric and titrimetric methods based on the primary amino groups 
of gentamicin were investigated but neither proved to be suitable 
for routine analysis.
A high-pressure liquid chromatographic method for routine control 
of the composition of gentamicin in commercial samples and 
formulations is described. The method utilises pre-column derivatis- 
ation followed by reversed phase chromatography with fluorescence 
detection and uses an internal standard for quantitation. Analysis 
of nineteen samples of gentamicin from various sources indicates 
that the ratio of major components and the content of minor consti­
tuents varies with the geographical origin of the sanple. The 
results were compared with those of a microbiological assay and 
the B.P. nuclear magnetic resonance (NMR) spectroscopic limit test 
of the same samples. The microbiological assay may be influenced 
by biologically active impurities whilst the NMR assay was insensitive 
to the presence of minor components. The method described offers a 
discrimating and flexible means of monitoring the composition of 
gentamicin.
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The same HPLC method was applied to the determination of 
gentamicin in plasma though it was not possible to use the internal 
standard. The method is rapid and specific and involves no extraction 
of gentamicin from the plasma. It would be suitable for both routine 
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Antibiotics may be defined as chemical substances produced by 
microorganisms, which have the capacity to inhibit the growth of 
bacteria and may be classified into a number of categories on the 
basis of their chemical structures. Gentamicin, the subject of this 
work is one of a group of carbohydrate units involved are mainly 
amino sugars and include an aminocyclitol ring which may be either 
streptamine (I) or 2-deoxystreptamine (II) (1) (Figure 1).
OH I: R = OH 
II: R = H
The 2-deoxystreptamine component is readily isolated by acid 
hydrolysis of aminocyclitols. It is 1,3-diamino-4,5,6-trihydroxy- 
cyclohexane and was first described as a degradation product of 
neomycin A and called neamine. Subsequently it was shewn to be 
closely related to the streptamine moiety of streptomycin which 
led to the use of its now more common name of 2-deoxystreptamine
(2) (3).
The configuration was determined by proton magnetic resonance 
spectroscopy and was consistent with an all-trans stereochemistry 
for the substituent groups on the parent cyclohexane ring (4).
A further classification of these antibiotics depends upon 
the placement of substituent groups on the 2-deoxystreptamine ring. 
Representative of compounds having 4,6-substitution are the kanamycins 
(Figure 2), gentamicins (Figure 3) and sisomicins (Figure 4) while 
those having 4,5-substitution on the 2-deoxystreptamine ring are 
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Figure 3. Structure of the gentamicins











= H; R^ = H; R^ = NH^ Neomycin B
R^ = CH^NH; R^ = H; R^ = H; R^ = NH^ Neomycin C





= H; R^ = mannosyl 
R^ = H; R^ = OH
Lividomycin A 
Lividomycin B





R = Hj R^ = CHjNH 
R «= CH-NH,! R = H
Figure 7. Structure of the paromomycins
Gentamicin
1.1 Isolation
In 1963 Weinstein and co-workers (5, 6) reported a new, basic, 
stable, water-soluble,broad-spectrum, antibiotic conç)lex which was 
isolated frcm two new species of the genus Micromonospora, specifi­
cally M. purpurea sp.n. (NRRL 2953)and M. echinospora sp. n. (NRRL 
2985). The taxonomy of this genus has been extensively studied by 
Luedemann and Brodsky (7) establishing the conformity of general 
features for species belonging to Micromonospora.
Isolation, purification and characterization of gentamicin was 
first performed by Rosselet et al. (8). Gentamicin can be readily 
extracted from fermentation broths by an ion-exchange procedure.
The pH of the whole broth is adjusted to 2.0 with strong mineral 
acid to release the bulk of the antibiotic from the mycelium. After 
filtration of the broth, oxalic acid is added to precipitate calcium 
ions and the solution is neutralized with strong alkali. Calcium 
is separated by filtration, the filtrate passed through a column 
containing AmberliteIRC-50 (Na^; 20 - 50 mesh) ion-exchange
resin, and the spent broth is discarded.
The antibiotic mixture, containing gentamicin and co-produced 
antibiotics, is eluted from the resin with strong mineral acid.
The neutralized eluate is then titrated with sodium dodecyl benzene 
sulphonate, precipitating most of the gentamicin C and leaving the 
co-produced antibiotics and some gentamicin C in solution. Gentamicin 
C dodecylbenzene sulphonate is separated by filtration, washed with 
water, partially dried and dissolved in methanol. The methanolic 
solution is passed through a column containing Amberlite IRA 401S
Fermentation broth
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Figure 8. Isolation of gentamicin C complex from fermentation broth.
ion-exchange resin to regenerate gentamicin fran its salt form. The 
procedure is summarised in Figure 8.
Lee and co-workers (9) have developed another method for the
extraction of the complex. The pH of the whole broth is adjusted to
2.0 with sulphuric acid, stirred and filtered. The pH of the filtrate
is adjusted to 7.0 with concentrated ammonium hydroxide then passed
through a column of IRC-50 resin (NH^ form). The resin is washed
with water and eluted with 2N NH.OH. The eluate is concentrated and
4
air dried to give a dark brown mixture which is then passed through 
a column of IRA-401S resin (OH form) and eluted with water. Eluates 
collected between pH 8 and 12 are combined and air-dried. After 
decolourisation this mixture is passed through a column containing 
Dowex 1x2 resin (OH form) and the gentamicin complex eluted with 
water.
Lee £t al. (10) subsequently described a method for the recovery 
of gentamicin from fermentation broth in which a foam separation 
process was evaluated using a batch system. The foam separation 
technique is based on differences in the surface activity of diff­
erent materials which may be molecular, colloidal, or macroparticulate 
in size. Materials with high surface activity are selectively 
adsorbed or attached at the surface of bubbles rising through the 
liquid, and are thereby concentrated and can be separated. A 
substance that is not surface active itself can often be made 
effectively surface active by using suitable surfactant agents.
Species without surface activity that are separated in this manner 
are called colligends and the surface active agents used to separate 
them are called collectors. This method enables the use of mild
conditions for stability of product, high separation efficiency when 
the specificity is properly exploited and allows fast separation 
by making use of a large interfacial area. In Lee's work, the 
gentamicin was a colligend and sodium dodecyl sulphate the most 
effective collector. From the experimental results, the optimal 
operating conditions selected were a pH below 9.0 and a collector- 
to-colligend ratio of 3:1. Bubbles were generated by pumping air 
into the mixture at a rate of 0.5 volume air/volume liquid/minute. 
Under these operating conditions, the average recovery of gentamicin 
was 73%.
1.2 Biological Activity
The antibacterial activity of gentamicin has been studied by 
Weinstein £t al. (11-13) and other workers (14-17). Gentamicin is
active against some Gram-positive and Gram-negative bacteria, 
particularly species of Pseudomonas, Proteus, Staphylococcus and 
Streptococ eus
1.3 Mechanism of action
Hahn and Sarre (18) showed that protein synthesis by susceptible 
bacteria failed within minutes of adding gentamicin to the cultures 
whilst biosynthesis of deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) remained relatively unaffected for some time. From these 
observations it has been concluded that inhibition of protein syn­
thesis is a specific effect of gentamicin and not merely the 
result of a more general disturbance of the metabolic processes.
This conclusion is supported by the observation that gentamicin 
inhibits polymerisation of phenylalanine in a ribosome polyuridine 
cell-free system. Gentamicin acts by binding to the 30s particle of
the ribosome with the resultant formation of an aberrant protein 
synthesis complex that is incapable of participating in the biosyn­
thesis of protein (19).
1.4 Resistance
Resistance to the aminoglycoside antibiotics is known and can 
be due either to ribosomal resistance or to the presence of amino­
glycoside-inactivating enzymes.When bacteria are successively 
cultured in a medium containing an aminoglycoside, resistant clones 
are readily obtained in which the ribosomes are no longer sensitive 
to aminoglycosid es (25). Other gentamicin resistant organisms have 
been shown to possess enzymes that chemically modify the molecule 
via acétylation or adenylylation (Figure 9) to produce inactive 
derivatives (20-26).
Enzymes AAC (3) - I, AAC (2') - II and ANT (2") would also 
confer resistance to kanamycin C, gentamicin A and sisomicin whereas 
enzyme AAC (S') - I would not. Conversely certain kanamycin 
resistant organisms produce a 3 '-hydroxy phosphorylating enzyme 
and thus are susceptible to gentamicin which lacks this hydroxy 
group (27-29).
1.5 Clinical use
Clinical studies by Rabinovich e^ al.(30), Sweeder et al. (31), 
Graber et al. (32)and Jao and Jackson (33) confirmed its value as 
a broad-spectrum antibiotic especially in cases of urinary tract 
infection due to Pseudomonas aeruginosa and the Klebsiella aerobacter 















Gentamicin R = R' = CH^
Gentamicin C^, R = CH^; R' = H 
Gentamicin C , R = R' = H
AAC (3) - I = Aminoglycoside-3-N-acetyl-transferase - I
AACC2') - II - Aminoglycoside-2'-N-acetyl-transferase - II
AAC(6') - I = Arainoglycoside-6*-N-acetyl-transferase - I
ANT(2") = Aminoglycoside-2"-0-nucleotidyltransferase
Figure 9. The enzymatic inactivation mechanisms.
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1.6 Therapeutic levels
Peak gentamicin levels of 4 yg to 8 yg/ml of blood are generally 
accepted as being adequate for treating serious Gram-negative bacillary 
infection (34-42). Trough levels of 2 yg/ml or greater and peak 
levels of 12 yg/ml or greater during the administration of a normal 
dose of gentamicin have been associated with an increased risk 
of toxicity (43,44).
1.7 Distribution in the Tissues
Gentamicin is poorly absorbed via the intestinal tract (45) 
but readily absorbed on intramuscular injection and also via otic 
administration (11)in an as yet unknown manner. Studies with 
radioactive gehtamicin showed that in blood 10% was associated 
with erythrocytes, 30% with plasma protein and 60% in solution 
(46-49). Gentamicin diffuses readily into thoracic duct lymph 
but not into the cerebrospinal fluid of most patients with uninflamed 
meninges (50). Gentamicin is excreted almost exclusively through 
the kidneys in patients with normal renal function, and high levels 
of the unchanged drug appear in the urine. Thus excretion is 
delayed where renal function is impaired, leading to an increase in 
the serum half-life to more than its normal value of about 120 
minutes (51-57).
1.8 Toxicity
The three major toxic effects associated with gentamicin are 
ototoxicity (58-62), nephrotoxicity (63-70) and neuromuscular 
blockade (71), The principal toxic effect of gentamicin on the 
inner ear is a loss of vestibular function caused by damage to the 
hair cells (72). Jackson and Arcieri (43) have produced an
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exhaustive review of the cases of gentamicin ototoxicity. They found 
that a majority of cases showed vestibular damage alone and a 
smaller proportion of the patients showed auditory damage alone, 
with only small numbers having both types of toxicity. More than 
half the cases of vestibular ototoxicity recovered, and in about 
half the instances of auditory ototoxicity damage was mild and 
restricted to the loss of high tones. Early detection of the signs 
of ototoxicity and discontinuation of the drug are essential to 
prevent irreversible damage (58). Nephrotoxicity caused by genta­
micin appears as an acute necrosis of the proximal tubular cells 
of the kidney (73-77). Renal damage is usually reversible if the 
drug is discontinued at the first sign of renal dysfunction (78). 
Experiments with animals have shown that gentamicin has the ability 
to potentiate neuromuscular blockade where neuromuscular blocking 
drugs have been used (79).
1.9 Dosage Forms
Gentamicin is currently available for topical use and parenteral 
injection. Topically, gentamicin is used in a 0.1% ointment or 
a 0.1% cream and is effective against primary and secondary 
bacterial infections. Parenterally, the drug is used against 
susceptible Gram-negative infections. It is effective in infected 
surgical wounds, severe soft tissue, respiratory and urinary tract 
infection (80).
The usual dose of gentamicin given by intramuscular injection 
is 400 to 800 yg per kg body weight every 8 hours. In severe in­
fections up to 5000 yg per kg may be given daily in divided doses.
The usual dose for children is 3000 to 5000 yg per kg every 24 hours
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in divided doses; infants and neonates may be given higher doses 
of 6000 to 7500 yg per kg daily in divided doses (81-92).
The course of treatment is generally limited to 7 days.
Gentamicin has been given intravenously (43) in the same 
doses that are used intramuscular by. It has sometimes been given by 
mouth for enteric infections and to suppress intestinal flora. In 
the treatment of meningitis it has been administered intrathecally 
or intraventricularly in doses of 1000 or 2000 yg daily in conjunction 
with intramuscular therapy. Doses of 10,000 or 20,000yg have 
been given by subconjunctival infection (93,94).
1.10 Chemical description and structure
The isolation and preliminary chemical studies (8) demonstrated 
that gentamicin is a complex of aminoglycoside antibiotics con­
taining the aminocyclital 2-deoxystreptamine and two additional 
amino sugars. The conplex is isolated as an optically active 
amorphous powder. It is readily soluble in water, pyridine and 
dimethylformamide, moderately soluble in methanol, acetone and 
ethanol, and insoluble in diethyl ether, benzene and halogenated 
hydroc arbons.
Chromatographic separation of the gentamicin complex shows it 
to consist of 3 major components designated as C^, C^ and C^^ (95).
The structures of these major components have been elucidated by 
a combination of spectroscopic and chemical methods.
None of the gentamicin C components exhibits absorption in 
the visible or ultraviolet regions of the spectrum. Infrared spectra
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are identical for all and, in general, are indicative of their poly- 
amino nature (96).
Mass spectrometry gave peaks at m/e 477, 463 and 449 for 
gentamicin C^, and respectively corresponding to molecular
formulae of ^20^41^5^7 ^19^39^5^7 (97). The
difference of 14 mass units suggests that the three compounds differ
in their degree of méthylation. This was confirmed by NMR studies
which showed that all three components contained a tertiary C-methyl
group and an N-methyl group, but that gentamicin had an extra
secondary C-methyl whilst gentamicin had both this and an
additional N-methyl.
Acid hydrolysis of gentamicin C yielded 2-deoxystreptamine 
(Figure 1) (98). Methanolysis (98,99) produced an unusual amino-
monosaccharide termed methyl garosaminide(Figure 10) and three 
different pseudodisaccharides, the gentamine (Figure 11).
OH
/HN-^ '''o h TH,OCH3
H j p





Figure 11. Structure of gentamine C
R = = CH^; Rg = H gentamine
R = CH^; R^ = R^ = H gentamine
R = R^ = Rg = H gentamine
Garosamine was shown by chemical means and high resolution NMR 
(100-102) to be 3-deoxy-4-C methyl-3-methylamino-L-arabinopyranose 
(Figure 12).
h x - hn
Figure 12. Structure of garosamine.
Per-N-acetyl gentamines were subjected to mercaptolysis to 
yield N,N'-diacetyl-2-deoxystreptamine and three crystalline diethyl- 
dithioacetal derivatives of a group of new aminosugars known as the 
purpurosamines (98). These were identified by NMR as 2,3/4,6-tetra- 
deoxy-2,6-diamino sugars with the structures shown in Figure 13.
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Their structures are represented by Figures a, b and c for the 
compounds derived from gentamicin C^, and C^^ respectively.
Periodate oxidation (98) and NMR spectroscopy established the 
position and linkage of purpurosamine and garosamine to 2-deoxy­
streptamine Thus the structures of gentamicin C^, and C^ were 
deduced to be as in Figure 3.
Recently a ^^C NMR study of a number of aminoglycoside anti­
biotics and their hydrolysis fragments has confirmed these structures 
(103).
Optical rotations were performed by Kershner (104) who found 
that each of the gentamicin C components is dextrorotary. The same 
author also suggested that the gentamicin C con^lex consists of 
six compounds rather than three. These are designated, in order of 
separation by counter-current distribution, in a chloroform: 
methanol:17% ammonium hydroxide system, as C^, Cg^, C g^,
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^ 2-111 ^la* Thin-layer chromatography showed that  ^ and
C migrate identically as do C_ and C. . Structural studies 
z-ii /-III la
indicated gentamicin to be an isomer of gentamicin with a 
C-6 methylaminopurpurosamine rather than a C-6 angular C-methyl group. 
The structures of C g ^  and C^ have been proposed to be diastereo- 
isomeric about the asymmetric C-6 carbon of purpurosamine.
Kershner (104) also proposed that gentamicin C^ differed 
from gentamicin C^^ in having the L-manno configuration of the pur­
purosamine as opposed to the D-gluco configuration of all the other 
gentamicin C components.
The nomenclature used by Kershner (104) differs from that used 
by other authors as shown in Table 1. In this thesis the nomenclature 
of Daniel et. al. (105,106) will be used.
In common with some other aminoglycoside antibiotics, the 
gentamicins are able to form chelates with divalent transition 
metal cations, notably copper (II), cobalt (II), nickel (II), 
manganese (II) and magnesium. Structural studies indicate a complex 
arrangement of metal to gentamicin possibly as an extended lattice 
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1.11 Assay of Gentamicin
1.11.1 Microbiological assay
The basic procedure for most microbiological assays of 
gentamicin is an agar-diffusion method. This involves the use of 
a suitable agar medium carrying a test organism that is sensitive 
to the antibiotic to be assayed. Standard solutions of antibiotics 
and unknown samples are placed in wells punched into the agar plate. 
After incubation for 12 to 48 hr, the zones of growth inhibition 
of the test organism around the wells are measured and compared 
with the standards to determine the antibiotic potency of the 
unknown samples.
Microbiological assays in general provide versatility and 
simplicity and are relatively inexpensive, but have several dis­
advantages. Firstly, the time required for conventional micro­
biological assays is 12 - 48 hours, although microbiological assays 
with shorter incubations (4-6 hr) have been described for genta­
micin (108-110). Secondly, the basic procedure is not specific 
and thus will not allow an accurate assay of gentamicin in the 
presence of other antibiotics. This problem arises in assying 
the serum levels in patients who are receiving other antibiotics 
in additional to an aminoglycoside. This interference can be cir­
cumvented by removing the interfering antibiotics, by adding a 
substance to the sample or medium that will inactivate the potentially 
interfering agent (s), or by using a test organism that is susceptible 
only to the aminoglycoside.
Oden et al. (Ill) described two microbiological assays for
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gentamicin. A standard curve disc-plate assay with Staphyloccus 
aureus ATCC 6538P was used for the analysis of raw materials. The 
method used for serum determinations was a standard curve cylinder- 
plate assay utilizing the more sensitive Bacillus subtilis ATCC 6633 
as the test organism.
Carlstrom et al. (112) used electrophoresis in agarose gel to 
identify and quantify gentamicin in seirum in the presence of carbeni- 
cillin, rifampin and clindamycin. After the drugs had been separated 
by electrophoresis, indicator bacteria in a thin agar layer were 
overlaid and the zones of growth inhibition determined.
Sabath e^ al. (113) reported a determination of gentamicin in 
0.08 ml samples of serum or plasma with a modification of the 
standard agar diffusion method. Gentamicin was assayed, in the 
presence of penicillins or cephalosporins by inactivating them 
with a zinc-requiring"broad-spectrum" 3-lactamase. The use of 
multiple-antibiotic-resistant strains also allows determination 
of gentamicin in the presence of other commonly used antibiotics. 
Alcid and Seligman (114) determined gentamicin concentration using 
a multiple-antibiotic-resistant strain of Staphylococcus epidermidis 
in an agar well diffusion assay.
Rapid gentamicin bioassays have been described by Warren et al.
(115) using Staphylococcus aureus ATCC 6538 P and by Lund et al.
(116) using a multiple-antibiotic-resistant strain of Klebsiella 
pneumoniae. The results were obtained in 2 - 4 hr.
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In addition to these methods which directly measure bacterial 
inhibition a number of assays have been based on other consequences 
of the antibiotic's effect on bacteria.
Urban (117) described a rapid micromethod for gentamicin assay 
in serum by utilization of bacterial reduction of nitroblue tétra­
zolium. The reduction of colourless nitroblue tetrazalinm (NET) 
to dark blue formazan by Escherichia coli is diminished by pre­
incubation with antibiotics. The method has been modified to 
allow assays on as little as 50 yl of serum containing 0.2 - 5.5 mg/1 
of gentamicin.
Rapid bioassays of gentamicin in clinical serum specimens, 
based on determination of adenosine triphosphate (ATP) levels in 
bacterial cultures exposed to gentamicin, have recently been developed, 
Harber and Asscher (118) determined the total ATP level in bacterial 
cultures, and Nilsson e^ al. (119) selectively determined the intra­
cellular ATP levels. Both methods require extraction of intracellular 
ATP. Nilsson (120) described the relationship between intracellular 
and extracellular ATP levels in Escherichia coli cultures exposed to 
various concentrations of gentamicin. The bioassay compared serum 
specimens with standard solutions of gentamicin.
Jacob et al. (121) and Noone et al. (122-125) described the use 
of a method based on the monitoring of the pH change brought about 
by the urease activity of Proteus mirabilis. Proteus species can 
split urea enzymatically with the production of ammonia and a 
consequent rise in pH. The presence of antibiotics reduces this
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activity and a less rapid rise is observed. Since gentamicin is 
most active in alkaline solution, it seemed possible that a 
sensitive assay method could be devised based on this effect.
Another method which depends on pH measurements has been 
described by Faine and Knight (125). The method achieved an accuracy 
and reproducibility ccmparable with plate methods but took only 90 
mins to complete. The principle is based on the measurement . 
the fall in pH in a culture containing a heavy inoculum of 
Klebsiella aerogenes. Fermentation is inhibited by antibiotic 
thus slowing the fall of pH. The rate of the pH change is related 
to the concentration of antibiotic.
1.11.2 Enzymic Assay
Daigneault ct al. (127) presented a detailed account of
various enzymes which transfer adenyl, acetyl and phosphoryl groups 
to various positions of the three six-membered rings of the amino­
glycosides. These enzymes are often present in organisms that 
carry resistant (R) factors and are believed to be responsible 
for the inactivation of gentamicin. These enzymic reactions form 
the basis of several radioenzymatic assays which have been developed 
for gentamicin (128-133).The principle of this assay depends on the 
specific enzymatic transfer of a radioactive modifying group to 
gentamicin. Different workers have employed different enzymes. Thus 
Smith at al. (128) used enzyme isolated from a mutant of Escherichia 
coli which transfers adenyl groups from ATP to the 2" position of 
gentamicin. Adenylated gentamicin, but not ATP, is positively
charged and therefore binds to a negative-charged phosphocellulose 
ion exchange paper. When aliquots of a reaction mixture, containing
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C-ATP, are pipetted onto phosphocellulose paper and washed to 
eliminate non specifically bound radioactivity, the phosphocellulose 
bound radioactivity is a measure of the adenylated antibiotic.
Shannon and Phillips (134) described an assay for gentamicin
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in serum, plasma and urine which used j^ l- ^cj acetyl coenzyme A 
and aminoglycoside 2'-N-acetyltransferase, an enzyme which acetylates 
all 3 major components of gentamicin. The separation of acetylated 
gentamicin from acetyl donor was again achieved by the use of 
phosphocellulose paper.
5'-N-acetyl transferase is less advantageous since it does not 
detect gentamicin which lacks a primary 6' amino group.
Williams et al. (137) described a spectrophotometric assay
for gentamicin in blood serum. The assay used a purified enzyme 
from Escherichia coli JR 88/C600 which catalyzes the acétylation of 
gentamicin with the production of coenzyme A. CoA production is 
linked to a chemical reaction with a sulphydryl reagent to produce 
stoichiometric amounts of a sensitive chromophore which can be 
monitored in the visible spectrum.
gentamicin + acetyl CoA -----> acetyl-gentamicin + CoASH (1)
Sulphydryl groups rapidly react with 5,5'-dithiobis-(2,2) 
nitrobenzoic acid to produce a stoichiometric amount of a disulphide 
and thionitrobenzoic acid as shewn in reaction (2)
HOOC  ___ .COOH HOOC  COOH (2)
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Thionitrobenzoic acid production was monitored by recording 
the increase in absorbance at 412 nm. The components of reaction (2) 
do not affect the progress of reaction (1).
Enzymatic assays have the advantage of simplicity, accuracy 
and reproducibility and correlate well with both microbiological 
and radioimmunoassays (135) . They are about as sensitive as 
microbiological assays and can be completed in 2 to 3 hr. A 
particular disadvantage when applied to gentamicin in serum is 
that the presence of carbenicillin gives low values perhaps due to 
the formation of a gentamicin-carbenicillin adduct (136).
1.11.3 Immunoassays of gentamicin
Immunoassays depend upon the ability of specific antibodies 
to bind to the antigens which were used to stimulate their production, 
If labelled and unlabelled antigens are mixed with the appropriate 
antibody they compete for binding sites, the proportion of the 
labelled antigen bound reflecting its abundance in the mixture.
Thus if calibration curves are prepared using known amounts of 
unlabelled antigen and antibody it is possible to estimate the 
amount of antigen in an unknown sample. Free and bound drugs may 
be separated by various methods such as electrophoresis, solid-phase 
adsorption, or chromatography (138-141). If the antibodies used 
were raised in eg. rabbit separation may be achieved by adding 
anti-rabbit gamma globulin to precipitate the antigen and anti­
body complex (double antibody method). In the double-antibody method 
the reaction mixture is centrifuged and the radioactivity in the 
precipitate is assayed.
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A major advantage of the radioimmunoassay method is its high 
sensitivity (micrograms per litre of serum) . If standards are pre­
pared in advance, the assay can be performed in about 2 hr. The 
lack of a radioactive measurement facilities in many clinical lab­
oratories, the necessity of handling radioactive materials, and its 
relatively high cost are major disadvantages of radioimmunoassay. 
Also essential to radioimmunoassay are a purified form of antigen 
for radiolabelling and also antibodies to the antigen. Because 
aminoglycoside antibiotics are not highly immunogenic, these haptens 
must be conjugated to a carrier protein, for specific antibodies 
to be raised.
Ashby et al. (142) described a single radioimmunoassay that 
can measure gentamicin, tobramycin and amikacin in the same sample, 
concurrently. A single reagent system composed of a pool of three 
very specific antisera was used in the procedure. The antisera 
combination did not alter the specificity of the procedure. Diff­
erent dilutions of antisera to these drugs are combined to give
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45 - 55% initial binding of the I-labelled antibiotics. lodinated 
derivatives of these three antibiotics were prepared by a modified 
Bolton and Hunter procedure (143). This assay measures all three 
aminoglycosides with a single assay system. Recovery and precision 
were excellent, but a longer time was needed to optimize the whole 
system. The short shelf-life of ^I-labelled antibiotics may also 
be a problem.
Shaw et al. (144) described a determination of serum gentamicin 
by a non-isotopic immunoassay. The method is based on partial
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quenching of fluorescence observed when fluorescein-labelled genta­
micin is bound by anti-gentamicin serum. The fluorescence intensity 
of the labelled gentamicin in an unseparated immunoassay incubation 
mixture therefore serves to indicate the extent of binding, which 
is related to the amount of competing unlabelled gentamicin The 
method is termed "quenching fluoroimmunoassay".
Wason e^ al. (145) reported a polarisation fluoroimmunoassay for 
gentamicin based on detection of the extent of antibody binding of 
fluorescein-labelled gentamicin by measuring fluorescence polarisation. 
The principle is that gentamicin-fluorescein isothiocyanate-gentamicin^ 
antibody complexes scatter incident polarized light to a much greater 
degree than do the small molecules of gentamicin-fluorescein iso- 
thiocyanate, and antibody binding can be assessed by changes in 
fluorescent intensity.
Burd et al. (146) reported a homogenous reactant-labelled 
fluorescent immunoassay for the measurement of therapeutic gentamicin 
concentrations in human serum. A derivative of umbelliferyl-g-galactoside 
was coupled covalently to the drug and this conjugate was found to 
be non fluorescent under assay conditions but fluorescent umbelliferol 
could be released by the action of 3-galactosidase. When the drug/dye 
conjugate was bound to anti-gentamicin antiboy it was inactivated 
as an enzyme substrate. This inactivation was relieved by the presence 
of gentamicin in competitive binding reactions. Hence, the rate of 
production of fluorescence was proportional to the gentamicin con­
centration. This assay required only 1 yl of serum.
Standefer and Saunders (147) described a technique in which a 
peroxidase-gentamicin conjugate was mixed with a gentamicin standard
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or serum together with an immobilised gentamicin antibody. The extent 
of the binding of conjugate to the antibody was observed by adding 
a chromogenic substrate for the peroxidase reaction. The absorbance 
of the product was inversely proportional to the amount of gentamicin 
in the reaction well. This assay can be completed in 30 minutes.
A haemag^lutination inhibition assay for gentamicin has been 
described by Mahon et al. (148). Antigen in the form of gentamicin 
complexed to bovine serum albumin was covalently attached to sheep 
erythrocytes. When antiserum to this complex was added to a sample 
containing more than 10 mg of the drug per litre, haemagglutination 
was inhibited.
A non-equilibrium enzyme immunoassay of gentamicin in serum 
was described by Mattiasson e^ al.(149). This method utilized a 
thermometric enzyme-linked immunoadsorbent assay (TELISA). A 
microcolumn filled with a polymer support containing covalently 
bound antibodies and well insulated from the surroundings was used.
The gentamicin sample was mixed with a known amount of gentamicin- 
catalase conjugate prior to passage down the column. On passage 
of the sançile through the immunosorbent in the enzyme thermistor 
column, competitive binding of native and enzyme labelled antigen 
to the antibodies takes place. The amount of enzyme bound to the 
column was measured by introducing a pulse of a suitable substrate.
The extent of reaction was determined by measuring the temperature 
change produced. The amount of enzyme bound is a function of the 
concentration of native antigen in the sample.
Phillips et al. (150) have compared, in a clinical laboratory.
28
three methods for estimating the concentration of gentamicin in 
serum. The adenylase method is most accurate, but requires considerable 
skilled technical time and expensive apparatus. The urease method 
requires an accurate pH meter but is otherwise inexpensive. Although 
it produces results most rapidly, it requires considerable technician 
time and is the least accurate. The agar diffusion method requires 
no expensive apparatus, least technician time, and produces results 
of acceptable accuracy. It does, however, take longer than the other 
two methods to produce results.
1.11.4 Spectrophotometric and spectrometric analysis of gentamicin
1.11.4.1 Colourimetry
The reaction of gentamicin with ninhydrin has been used 
to determine gentamicin in pure preparations (151). Kartseva 
(152) has described a method based on the ability of gentamicin 
to form a coloured complex with copper to control the preparation 
and purification of commercial gentamicin.
1.11.4.2 Fluorimetry
Csiba (153) presented a chemical method for the quantitative 
determination of gentamicin in biological fluids. Gentamicin was 
separated frcxn serum and urine by ion exchange chromatography and 
determined spectrofluorometrically by means of a fluorescent di- 
hydrolutidine derivative. This was formed by condensation of the 
primary amino groups with acetylacetone and formaldehyde, under 
acidic conditions (pH 2.6).
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1.11.4.3 Proton magnetic resonance spectrometry
The proportions of the main components present in gentamicin 
sulphate can be monitored by nuclear magnetic resonance spectrometry 
(154). The method depends on the measurement of the peak height of 
signals due to N-methyl and C-methyl groups present in all three 
main components and of those present in C^ and C^ only. By defining 
peak height ratios the composition of gentamicin may be specified 
within acceptable limits. The purity and potency must be controlled 
by other means. The proton magnetic resonance method is very rapid, 
simple in execution and applicable both to the bulk antibiotic 
and to the injection formulation. However, it is capable of providing 
control only over the relative proportions of the gentamicin C com-r 
ponents. It provides no control over other gentamicins nor over 
the proportion of gentamicin C complex in the. material.
1.11.4.4 Mass spectrometry of gentamicin
This technique depends on the ionization and mass fragmentation 
of compounds by high voltage and the subsequent separation of the mass 
ions in a magnetic field. Daniels et al. (97) investigated the 
electron impact and isobutane chemical ionization mass-spectral 
fragmentation pattern of gentamicin components C^, and 
Parfitt e^ al. (155) used chemical ionization and field desorption 
mass spectrometry. According to these authors, field desorption 
under optimum conditions resulted in little glycosidic cleavage 
and the [m + iJ"^  ions dominated in the spectra. These methods can 
show the component profiles in commercial gentamicin samples.
Related compounds as trace impurities may be identified by their 
|m  + hJ^ ions.
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1.12 Separation of gentamicin components
Commercial gentamicin C is known to be a mixture of several 
related antibiotic substances. A number of methods have been developed 
to separate, characterise and quantify the individual components.
1.12.1 Paper chromatography
Table 2 shows a comparison of Rf values of the major genta­
micin components C^, and using various mobile phases.




80% methanol plus 3% sodium 
chloride (wt/vol)(l:l),
descending^ 0.57 0.56 0.48 1
propanol:pyridine:acetic acid:
water (6:4:1:3),ascending (v/v) 0.34 0.30 0.22 1
80% phenol,ascending (v/v) 0.45 0.45 0.45 1
chloroform:methanol:17% b b b
ammonia (2:1:1)^ 0.67 0.40 0.21 95
156
a = paper buffered with 0.95M Na^SO^ and 0.05 M NaHSO^ 
b = R^ = distance of zone from origin/distance from origin to 
end of paper at t = 6h 
c = lower phase.
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1.12.2 Thin-layer chromatography
Table 3 shows a comparison of various thin-layer chromatographic 
methods for the separation of the gentamicin complex
Support material and solvent system







Chrom AR^(Silicic acid - glass 
fibre sheets),chloroform: 
methanol: 28% ammonia 
(2:1:1) 0.63 0.37 0.20 157
Silica gel G, chloroform; 
methanol: conc. ammonia 
(1:1:1)* 0.44 0.39 0.35 158
These workers also detected six minor components which they 
designated gentamicin X^, X^, X^, X^ and X Their Rf values
were 0.48, 0.31, 0.27, 0.25, 0.23 and 0.18 respectively.
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Table 4 shows the Rf values in various systems for some of 









la - - 0.20
Gentamicin C^ — — 0.37
Gentamicin C^ - - 0.63
Gentamicin A, ^ 0.0 0.36 0.10
Gentamicin A 0.0 0.41 0.16
Gentamicin B 9.0 0.52 0.22
Gentamicin X 13.5 0.55 0.28
Gentamicin B, 27.0 1.00 0.40
-p _ distance component from origin
F 1 distance component B^ frcxn origin
Present in component A as a trace
System No. 1. chloroform - methanol-17% ammonia (paper)
System No. 2. :2-butanol - tert - butanol - methanol - 27% ammonia 
(paper)
System No. 3. Chloroform - methanol - 28% ammonia (TLC)
In both TLC and paper chromatography a number of methods have 
been used to detect the compounds. The most usual is ninhydrin 
used under acidic (158) or basic (1) conditions. Alternatively 
a microbiological method may be used either by means of a bio­
autographic technique (1, 153, 160-162), or be eluting the 
compounds prior to a microbiological assay (163). This latter method 
affords a means of quantifying the components. Quantification after
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spraying with chemical reagents has also been achieved by densito- 
metric (158, 160, 161, 164) or fluorimetric (165) scanning.
1.12.3 Column chromatography
Ion exchange chromatography has proved useful both in isolating 
gentamicin C from co-produced antibiotics and in separating the 
components of gentamicin C. Berdy e^ al. (166) isolated 25 amino- 
cyclitol antibiotics from the crude culture broth of Micromonospora 
purpurea var. nigrescens MNG-122 strain by means of repeated chroma­
tography on carboxyl - or sulphonyl-type ion-exchange resins and 
dextran gels. Gentamicin C^, C^, A, B, B^, X^, sisomicin,
garamine, gentamine and sevens other compounds were identified. 
Gentamicin A has also been isolated by chromatography on Dowex 
1 x 2  (167).Thomas and Tappin (151) used cellulose phosphate P 11 
to separate commercial gentamicin C into four major and three 
minor components. These all showed optical activity and gave a 
positive reaction with ninhydrin but only the four major components 
were microbiologically active.
The gentamicin C complex can be separated into 3 major components 
by employing cellulose or chromosorb W chromatographic columns with 
chloroform, methanol and 17% ammonia as the solvent system (95).
Cooper et al. (102) used silica gel with the solvent system chloro­
form, isopropanol and concentrated ammonia to isolate the major 
components of gentamicin C on a preparative scale.
Wagman et al. (159) has described a similar method for the 
separation of the minor constituents produced in the gentamicin 
fermentation by Micromonospora purpurea NRRL 2953. The column used
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was silica gel and the solvent system was chloroform, methanol and 
28% ammonia. Compounds isolated included gentamicin A, A^, B, B^ 
and X.
1.12.4 Counter-Current -Distribution
A Craig-type counter current distribution apparatus has been
used by many authors (104, 105,168) in the separation of the
gentamicin complex. Except for minor variations all of the reported
methods are very similar and use a solvent system composed of
chloroform, methanol and 17% ammonia. In addition to gentamicin
C , C and C this method also separates gentamicins C and C .
X Xâ. À 20
These relatively minor components have been identified as the 6'-C 
epimer of gentamicin C^ and 6'-N-methyl gentamicin C^^ respectively. 
(168). The microbiological activity of both components is sub­
stantially the same as gentamicin C^, C^ and C^^. The advantages 
of Craig distribution for the separation of the gentamicin C complex 
lie in its ability to handle large quantities of material and to 
separate the components without prior derivatization. However, 
the solvent system used is susceptible to large variations in 
saturation caused by relatively small ten^erature fluctuations (104). 
In addition, their relatively strong basicity allows for precipitation 
of atmospheric carbon dioxide as ammonium carbonate salts. These 
problems could also occur in those chromatographic systems which 
use a similar solvent mixture.
1.12.5 High-performance liquid chromatographic analysis of gentamicin 
Recently, "high-performance" liquid chromatography has been
suggested as a rapid, specific, and sensitive method for quantifying 
a variety of compounds, including antimicrobial agents (169). Its
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principles are essentially the same as in liquid-chromatographic
systems, in that separations are obtained by adsorption, partition,
ion-exchange, or gel filtration. Pressures of 3.45 - 41.4 MPa (500- 
2
6000 lb/ in ) may be applied to the column, and results obtained 
in minutes rather than hours or days as with conventional liquid 
chromatography.
The development of sensitive and specific detectors has been 
an important factor in the growth of usefulness of high-pressure 
liquid chromatography. Ultra-violet absorption is the most general 
method of detection in present use whilst fluorescence can provide 
even greater sensitivity and specificity. Since gentamicins 
contain neither a uv nor a fluorescent chromophore both these 
detection methods require the synthesis of suitable derivatives.
In fact fluorescent derivatives have received the most attention.
Several reagents are currently available for the fluorescence 
detection of primary amines (171).










Freeman et (176) described a variation of this reaction
in which the mercaptoethanol was replaced by thioglycollic acid.
ii) l-fluoro-2,4-dinitrobenzene (170,177, 178).





iii) 5-dimethylaminonaphthalene - 1 - sulphonyl chloride (Dansyl 
chloride). This reagent can also be used for alcohols (179).
SOzCl SOz-NH-R
R - N H z
N C C H a ^ z  N c C H s J j
For HPLC the derivatives may either be prepared before injection 
onto the column (pre-column derivatisation) or the reaction may be 
carried out in a post column reaction coil after separation of the 
components (post-column derivatisation).
Advantages which have been claimed for pre-column derivatisation 
are summarised below (170):
(1) Unlike post-column derivatisation, no restrictions are imposed 
by the solvent system used as mobile phase. Both reaction conditions 
and chromatographic conditions can be chosen freely.
(2) The rates of the reactions are not usually limiting for vitro 
reactions, whereas slow reactions can cause serious mixing and 
reaction-volume problems in post-column procedures.
(3) Derivatisation prior to chromatography can be used as a "pre- 
clean-up" step; selective reagents and extraction procedures can 
result in the elimination of much interference.
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(4) Excess reagents can usually be eliminated easily in contrast 
to reactions after separation.
(5) Chromatographic properties such as retention time and resolution
can be improved by a suitable choice of derivative.
(6) The choice of appropriate labelling reagents can result in 
suitable fragmentation patterns in mass spectrometric evaluation 
of the derivatives.
On the other hand, the limitations are:
(1) Side reactions might lead to more than one derivative and hence
more than one peak for a single compound.
(2) The reactions must be quantitative, or at least reproducible, 
in both standard and analysis assays.
Alternatively the advantages of post-column procedures are (170):
(1) The formation of artifacts is not very likely.
(2) Different detection principles can be utilized simultaneously.
The limitations of this mode of operation are:
(1) The eluent can strongly influence the reaction medium.
(2) In HPLC, high flow-rates occur through small columns. Therefore 
the rates of post-column reactions must be relatively rapid (< 30 
sec.), otherwise considerable dead-volume and reaction-volume 
problems ensue.
(3) A strict condition is that the derivatisation reagent must 
not be detectable under the conditions used for detection of the 
derivative.
Anhalt (107,180) has described a post-column derivatisation 
method in which the three major components were separated as ion
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pairs with pentane sulphonic acid. A reversed phase column with 
chemically bonded octadecylsilane (C^g) was used, eluted with a 
mixture of sodium pentanesulphonate, sodium sulphate and aqueous 
acetic acid solution.
Post-column derivatisation with 0-phthalaldehyde was carried 
out. Although these workers obtained reproducible results they found 
that the geometry of the post-column reaction coil did affect the 
fluorescence yield.
Several other workers have described methods which rely on pre­
column derivatisation.
Peng et al. (179) and Chiou e^ al. (181) chromatographed the 
dansyl derivatives on a microparticulate reverse-phase column which 
was eluted with aqueous acetonitrile. This method separated gent­
amicin from and C^.
The UV absorbant 2,4-dinitrophenyl derivatives were separated 
on a reverse-phase column (C^g) by elution with tris (hydroxymethyl) 
aminomethane in water and acetonitrile but this method did not
separate gentamicin C and C (177).
1 2
Maitra e^ al. (172) described the separation of all three major 
components as their 0-phthalaldehyde derivatives on a reverse-phase 
column (C^g) . The mobile phase was a mixture of methanol and water 
containing a specific amount of tripotassium ethylene diamine 
tetra acetate. Other ami noglycosides such as tobramycin and amikacin
40.
did not interfere with the assay. A similar method has been described 
by Back et al. (182).
A modification of the 0-phthalaldehyde reaction in which thio­
glycollic acid replaced mercaptoethanol has been proposed by Freeman 
et al. (176). By using these derivatives they separated all 3 major 
components and gentamicin by ion-pair chromatography on a
reverse-phase column. The mobile phase was a mixture of aqueous 
sodium heptane-sulphonate, anhydrous acetic acid and methanol.
These HPLC systems have been used for the quantitative analysis of 
the major components by the use of a suitable standard gentamicin 
preparation.
No derivatis.ation is required if a refractive index detector 
is used (107). This is relatively insensitive but is most suitable 
for preparative work.
1.12.6 Gas-liquid chromatography of gentamicin
The gas-liquid chromatographic separation of gentamicin 
requires the derivatisation of the -OH and -NH^ groups to yield 
sufficiently volatile and heat stable compounds.
Mayhew and Gorbach (183, 184)reported a rapid analysis of 
gentamicin in serum in which -O- silylated and -N- acetylated 
derivatives of gentamicin were examined on OV 17 at 262°C.
Gentamicin was resolved but and gave a single peak.
Normal serum constituents did not interfere with the chromatograms 
and neither did other drugs and antibiotics administered concurrently
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with gentamicin therapy. Quantitation was based upon the relative 
response of gentamicin to a fixed amount of the internal standard, 
kanamycin A. Isothermal chromatographic analysis time per single 
serum specimen was approximately 50 minutes.
Introduction to the Research Problem
The many chromatographic, structural and biological studies 
just described have yielded a large body of knowledge concerning 
this antibiotic. However, many important questions remain. In 
the analytical field these include:
1) Pharmacopoeial standards
The monograph for gentamicin sulphate (British Pharmaceopaeia, 
1980) (185) specifies proton nuclear magnetic resonance (NMR)
spectrometry as a method of monitoring proportions of the main 
components. The purity is controlled by thin-layer chromatography 
Sulphate determination is carried out by a gravimetric method with 
barium chloride solution and water content by Karl Fischer titration. 
The total potency of the compound is determined by biological assay.
The United States Pharmacopoeia, 1980 (186) specifies paper 
chromatography followed by bioautography as a method for controlling 
the proportions of gentamicin major components. Water content is 
determined by loss on drying.
2) The manufacture and quality control of formulations 
Total potency and purity are controlled according to the
monograph. In some cases an extraction method has to be used in 
order to remove other interfering substances.
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3) Accurate determination of serum levels
The aim of antibiotic therapy is to obtain a high enough 
concentration of the drug at the infected site to kill or inhibit 
the growth of the microbe. It would therefore be logical to measure 
the concentration of the drug in the affected tissue to ensure that 
the dose administered is adequate. However, such measurements are 
technically difficult to perform (it may not be feasible to obtain 
samples, it is difficult to recover drug from the tissue in a 
standardised manner) and concentration determinations are therefore 
usually done in samples obtained from serum and other readily available 
body fluids.
Not only must the clinician be sure that the administered 
antibiotic reaches effective concentrations in the body; he must 
also guard against undesirable side effects. Gentamicin possesses 
nephrotoxicity, ototoxicity and may cause neuromuscular blockade. 
Usually the appearance of toxic damage seems to be related to the 
concentration of the drug in the blood stream.
Thus, from the aspects of safety and efficacy, it is necessary 
to monitor gentamicin concentration during therapy. This is 
especially true when an abnormal rate of elimination can be 
suspected, for example in patients with renal diseases and in 
children.
Ideally, an assay technique for gentamicin concentration 
should be rapid, so that the answer is available prior to 
next dosage; it should be accurate; and it should be specific 
so that other antibiotics concomitantly administered do not cause
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a falsely high value.
Several methods have been developed to determine serum level of 
gentamicin. They include microbiological assay, enzymic assay, 
immunoassay and high-performance liquid chromatography.
(4) The chemical nature and biological activity of the minor components 
Many workers have observed minor components in gentamicin 
samples (158, 159). Many of these are unidentified and their bio­
logical activity (if any) is unknown. Thus the main objectives of 
the project were:
(a) To isolate as many as possible of the components of 
commercial gentamicin.
(b) To identify shme of the minor components and examine their 
biological activity.
(c) To use the pure major components as standards in developing 
an assay for gentamicin suitable for use with commercial 
raw materials, formulations and serum.
The recent work on the separation of the gentamicin complex 
by HPLC shows its potential as an analytical tool. Since it is 
possible to separate the major cexponents of the gentamicin complex 
it can potentially be used to determine component ratios in addition 
to the total amount of gentamicin. In addition to high specificity 
and sensitivity a major advantage is the speed of assay. Thus one 
of the objectives of this project has been to apply HPLC techniques 
to the assay of gentamicin in commercial raw materials, formulations 
and serum and to compare this method with existing official assays.
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CHAPTER 2
Chromatographic separation and characterisation of 
the components of commercial gentamicin C
Introduction
As mentioned in the previous chapter the gentamicin C complex 
has been shown to consist of at least three major components. The 
present chapter describes the chromatographic separation of gentamicin 
by paper chromatography, thin-layer chromatography, column chroma­
tography, and preparative high-pressure liquid chromatography and 
subsequent spectroscopic investigations.
Materials and Methods
2.1 Separation of the gentamicin C complex 
Materials
Gentamicin sulphate (mixture) was donated by Nicholas 
Laboratories Limited. Solutions of 20 mg/ml and 50 mg/ml in water 
were used for TLC and paper chromatography respectively. Chloroform,
methanol, ammonia solution, ethanol, acetone and glacial acetic
acid were obtained from Fisons Scientific Apparatus Limited.
Ninhydrin, silica gel for chromatographic adsorption, potassium 
permanganate, sodium hydroxide and pyridine were obtained from BDH 
Chemicals Limited on silica gel H and silica gel 60 were obtained
from Anderman and Co. Limited (U.K. distributors of E. Merck




2.1.1 Paper chromatography (185)
Paper chromatography was carried out by a descending technique 
using Whatman No. 20 paper.
The lower layer of a mixture of chloroform-methanol-concentrated 
ammonium hydroxide (sp. gr. 0.88)-water (10:5:3:2) was placed in the 
solvent trough. The chamber was saturated with solvent vapour by 
placing portions of both upper and lower phases in the bottom of 
the tank for 24 hours before use. 2 yl of gentamicin sulphate 
solution was applied to the paper and developed for 5 hours.
After drying at 105°C for one hour, the paper was sprayed with 
a freshly prepared solution of ninhydrin (0.25 g) in a mixture of 
equal volumes of pyridine and acetone and then heated for 2 minutes 
at 105°C. The gentamicin components were visible as purple spots on 
a white background.
The Rp value was calculated from
distance moved by the solute 
distance moved by the solvent
2.1.2 Analytical thin-layer chromatography (164).
Adsorbant
Silica gel 60 plates (20 x 20 cm) 0.25 mm thickness were 
heated for 1 hour at 135°C prior to use.
Solvent
The lower layer of a mixture of methanol-chloroform-concentrated
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ammonium hydroxide (sp. gr. 0.88) (1:1:1). Care was taken to ensure
that the chamber was saturated with solvent vapour. The plate was 
subjected to a single development to a height of 15 cm.
Visualisation
After drying at 135°C, the plate was sprayed with a freshly 
prepared solution of ninhydrin (1.0 g) in a mixture of 95% ethanol 
(50 ml) and glacial acetic acid (10 ml) and then heated for 15 minutes 
at 135°C. The gentamicin components were visible as purple spots 
on a white background.
This TLC system was affected by variation in temperature. To 
obtain reproducible results the chamber was placed in a thermostatically 
controlled water bath at 25 - 0.2°C. The solvent was changed after 
3 days use due to the loss of ammonia altering the solvent composition. 
This TLC system was used to monitor the results of subsequent prepa­
rative procedures.
2.1.3 Preparative thin-layer chromatography
The method used was the same as for analytical TLC, except 
that silica geliH was used to prepare layers of 1.0 mm thickness. 
After development,the plates were dried at room temperature and a 
small portion of the plate sprayed with 1% potassium permanganate 
solution whilst the rest of the plate was masked. The gentamicin 
components gave yellow bands on a pink background. The unsprayed 
portions of the plate corresponding to these, bands were scraped 
off and extracted with water for 3 hours. The solutions were con­
centrated and monitored by analytical TLC.
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In order to reduce losses due to decomposition, a similar plate 
was run in which the silica gel H was slurried with 0.05 M phosphate 
buffer, pH 7.0 instead of water.
2.1.4 Column chromatography
2.1.4.1 Formation of gentamicin base
Amberlite IRA 400 (Cl form) (30 g) was converted to the 
OH form by passing IN sodium hydroxide through the column until 
the eluate was basic. It was then washed with water until the 
eluate was neutral.
Gentamicin sulphate (300 mg) dissolved in water (0.5 ml) was 
applied onto the column and eluted with distilled water. The pH 
of the eluate was monitored and all the alkaline fractions were 
collected and combined. This was lyophilized to obtain gentamicin 
base as a vfhite solid.
2.1.4.2 Column chromatography using silica gel (60 mesh) (102)
Silica gel (25 g) was slurried with the lower phase of th 
solvent system chloroform-isopropnaol-17% w/v ammonia solution 
(2:1:1) and packed into a chromatographic glass column (1 cm i.d.). 
Gentamicin base mixture (200 mg) was dissolved in the same solvent 
(0.3 ml) and chromatographed using a flow rate of about 0.5 ml/mm. 
Fractions (1 ml) were collected automatically and monitored by TLC.
2.1.4.3 Colujn chromatography using silica gel H (TLC grade)
Silica gel H (16 g) was slurried with the lower phase of 
a mixture of chloroform-isopropnaol-17% w/v ammonia solution (2;1:1) 
ànd packed into a chromatographic glass column (2.5 cm. i.d.).
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Gentamicin base mixture (200 mg) was dissolved in the same solvent 
(0.3 ml), applied onto the column and eluted with this solvent.
The column was run at the rate of 0.3 ml/min and 3 ml fractions were 
collected, automatically. After 800 ml the elution was continued 
with a mixture of chloroform-isopropanol-concentrated ammonia 
solution (2:1:1). 6 ml fractions were collected. After 400 ml of
this solvent another change was made to the lower phase of a 
mixture of chloroform-isopropanol-concentrated ammonia solution 
(1:1:1). The fractions were monitored by TLC and those containing 
pure components were combined, the organic solvent removed under 
reduced pressure and the water removed by lyophilization.
2.1.4.4 Preparative high-pressure liquid chromatography
Instrument Jobin Yvon Chromatospac Prep.
Division d'instruments S.A.
Column 4 cm i.d.
Support Lichroprep^ Si 60
particle size 15 - 25 ym 
weight 200 g 
Flow rate 20 ml/min
Pressure 7.2 bar
Gentamicin base mixture (3.5 g) in the mobile phase (4 ml) 
was applied onto a column and eluted with the same mobile phase as 
for column chromatography(2.1.4.3).The instrument was equipped with 
a refractive inidex detector but as this was not sensitive enough 
to detect minor components, 10 ml fractions were collected auto­
matically and monitored by TLC.
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2.2 Spectroscopic examination of gentamicin components
2.2.1 Ultraviolet and visible spectra
Ultraviolet and visible spectra were recorded using Perkin- 
Elmer 550S UV-VIS double beam, recording spectrometer.
2.2.2 Infrared spectra
Infrared spectra were determined on a Unicam SP 200Ç 
Grating Infrared Spectrophotometer. The sample was prepared as a 
Nujol mull.
2.2.3 Mass Spectrometer
Field desorption mass spectra were determined by Dr.
D.E. (âmes at the Department of Chemistry, University College, 
Cardiff, using a Varian CH-5D mass spectrometer on-line to a Varian 
620 i computer. Methyl alcohol was employed as solvent, the source 
temperature was 80°C and optimum emitter currents were 17 to 18 mA.
Chemical ionization mass spectra were determined by Dr. R. Black 
at the Chemical Defence Establishments ,Porton Down, U.K., using a 
V.G. Micromass 7070 mass spectrometer. Isobutane was used as the 
reagent gas at a source pressure of 0.5 Terr. The source temperature 
was 200°C.
Electron impact mass spectra were determined by Mr. C. Cryer at 
the University of Bath, Department of Chemistry using an AEI single 
focussing mass spectrometer model No. MS12. The ionizing potential 
was 12 eV and the ion source temperature 180°C.
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2.2.4 Nuclear Magnetic Resonance
100 MHz proton NMR spectra were determined by Mr. D. Wood 
on a JEOL P.S. 100 NMR spectrometer (continuous wave), 90 MHz proton 
and carbon-13 NMR spectra were determined by Mr. J. Kountourellis 
on a JEOL FX 90Q Fourier Transform NMR spectrometer, at the University 
of Bath, School of Pharmacy and Pharmacology.
Results and Discussion
a) Separation of gentamicin C complex
1) Physical descriptions
As free bases, gentamicin C components are white, odourless, 
amorphous hygroscopic solid. They are highly soluble in water and 
methanol, less so in ethanol, and insoluble in acetone, ether and 
other less polar solvents.
2) Paper chromatography
Table 5 shows the separation of gentamicin C by this
method.





The three major components were well separated but no minor 
components were observed. This method was time consuming (5 hours) 




Figure 14 represents a chromatogram of the gentamicin C 
complex and the value of each individual components in comparison 
with the method of Wilson et al.(158).
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It can be seen that the three major components were well 
separated as were a number of minor components. Reproducibility 
of the method was obtained when the chrcmatographic chamber was 
placed in a thermostatically controlled water bath at 25 - 0.2°C.
The method of Wilson e^ al.(158) differs from the one presented 
here in that he used commercially coated plates (E.M. Laboratories 
Inc., New York) and ambient temperatures. The solvent system is 
the same. He observed six minor components, one less polar than 
gentamicin and five more polar than gentamicin These
cannot be correlated with any of the minor components observed during 
the present study owing to the wide differences in R^ values.
4) Preparative thin-layer chromatography
Both buffered and unbuffered plates gave very low recovery 
of gentamicin components. These were not pure and the evidence 
suggested that decomposition had occurred during the preparative 
procedure.
5) Column chromatography
The results of the two column and the high-pressure liquid 
chromatographic separations of gentamicin are shown in Tables 6, 7 
and 8.
Table 6 . The separation of gentamicin C using column grade silica gel
Solvent Compound
Chloroform:isopropanol : 17% ammonia (2:1:1)
Fractions 55 - 59 ml C^
58 - 70 Cg
6 0 - 7 0  C ■
la
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Table 7. The separation of gentamicin C using TLC grade silica gel,
Solvent Compound
Chloroform:isopropanol: 17% ammonia (2:1:1)
Fractions 111 - 123 ml CX5
135 - 147 cx.
156 - 204 CX3
225 - 318 s
309 - 321 CXi
345 - 450
510 - 675 ^la
Chloroform:isopropanol: conc. ammonia (2 :1 :1 )
120 - 150
180 - 240 cx^
Chloroform:isopropanol : conc. ammonia (1 :1 :1 )
360 - 600 CX4
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Fractions 2,200 - 2,600 ml CX^
2.500 - 2,700 CX^
2,800 - 3,600 CX^
3.500 - 5,200 C^
Chloroform:isopropanol:conc. ammonia (2:1:1)
Fractions 600 - 1,250 ml C^
1,200 - 2,700 C^^
3,700 - 4,000 CX^
b
5,180 - 6,180 CX
Chloroform:isopropanol: conc. ammonia (1:1:1)
Fractions 500 - 2,000 ml CX^
55
It can be seen that the relatively coarse column grade silica 
gel only partially separated the mixture and gave rise to mainly 
mixed fractions.
A similar column containing TLC grade silica gel gave much 
better resolution and allowed pure samples of all the major components 
and minor components which were designated CX^-CX^ to be isolated.
This column proved to be reproducible from run to run. However the 
column had a maximum capacity of 200 mg of gentamicin and took 
about 1 week to run. Although the HPLC system had a slightly less 
good resolution it enabled 3.5 g of gentamicin mixture to be separated 
in less than one day.
Both columns gave the elution order which would be predicted 
from the similar TLC system.
b ) Spectroscopic examination of gentamicin components
None of the gentamicin components exhibits absorption in the
visible or ultraviolet regions of the spectrum. Infrared spectra
were identical for all. The only notable feature was a broad peak
-1
in the 3,000 - 4000 cm region due to 0-H and N-H stretching.
1) Gentamicin C^, C^ and C^^
Field desorption mass spectra of these components show a 
quasimolecular ion (M + H)^ as the only intense line in each spectrum.
By contrast electron impact spectra give at best a very weak 
































spectrum of gentamicin C^.
Daniels e^ al.(97) suggested the fragmentations shown in the 
scheme in Figure 16. The fragmentation patterns of gentamicin 
and were similar to that of except for the difference in 
mass of the purpurosamine ring, and the lack of the fairly prominent 
peak at m/e 420 due to cleavage of the purpuros amine side chain.
In particular they pointed out that fragments with m/e 191, 173,
163 and 145 were characteristic of 2-deoxystreptamine containing 
antibiotics.































Fragments with m/e 151 and 163 are characteristic of the 
garosamine and 2-deoxystreptamine rings respectively. For the 
purpurosamine ring, fragments with m/e 157, 143 and 129 are 
characteristic of gentamicin C^, and respectively. The
garosamine moiety may also give rise to a peak of m/e 129.
Figure 17 shows the chemical ionisation mass spectrum of gentamicin
^1-
The chemical ionisation mass spectra show a prominent 
peak and a somewhat simpler fragmentation pattern which chiefly 




R = -CH - NH - CH.
T ■
R = -CH - NH^













|m  + h J ^ 478 (100) 464 (100) 450 (100)
B + C 322 (38) 322 (68) 322 (67)
C 160 (48) 160 (7) 160 (22)
B 163 (5) 163 (5) 163 (30)
A 157 (82) 143 '(17) 129 (22)
Cleavage of garosamine from the gentamicins gives rise to a 
weak ion at m/e 160 in all of the spectra whilst cleavage of the 
purpurosamine moiety gives the characteristic ions of m/e 157,
143 and 129.
It is noteworthy that there are no prominent peaks at m/e 319, 
305, 291 corresponding to a protonated gentamicin moiety (rings A + B) 
whereas the protonated garosamine moiety (rings B + C) gives a very 
prominent peak at m/e 322.
It is clear from the mass spectra that these major components 
of gentamicin differ in the degree of méthylation of the purpurosamine 
rings. This is confirmed by the proton NMR spectra shown in Figures 
19, 20 and 21. These spectra are in agreement with those obtained 
by Cooper £t ah.(98) and Daniels ^  al. (106) who assigned the 
peaks as follows. All the components show a singlet at 61.18 which 
conforms to a C-CH^ group (4"). The N-CH^ group (3") is shown by 
a singlet at 62.50. The anomeric protons occur as doublets at
61 .
Figure 19. PMR spectrum of gentamicin C
ppra
62.
Figure 20. PMR spectrum of gentamicin C
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65.04 and 65.12 (1" and 1' proton respectively). Doublets of 5"- 
equatorial and axial protons appear at 64.02 and 63.28 respectively. 
A quartet at 63.76 and a doublet at 62.54 indicate the presence of 
the 2"-equatorial and 3"-proton respectively. The 2-equatorial 
proton in 2-deoxystreptamine ring is characterised by a double of 
triplets at 61.94.
The differences between gentamicin and lie in their
degree of méthylation at 6 '-position of purpurosamine ring. Genta­
micin has the basic unmethylated ring whilst gentamicin 
shows a doublet at 61.04 corresponding to the secondary methyl 
group at C-6*. Gentamicin also has this peak plus a three proton 
singlet at 62.34 due to the -NH-CH^ group.
Figure 22 compares the PMR spectra of gentamicin base mixture 
and its sulphate salt. The major differences are the resonances 
of the anomeric protons, H-2" proton, H-5" equatorial and axial 
protons as shown in Table 9. One half of the doublet assigned 
to the secondary C-methyl group is masked by the tertiary C-methyl 
signal (61.36) in the spectrum of the sulphate.
Table 9 . Resonances of some of the protons in the free base and 
sulphate salt.
Proton Resonance peak (6,ppm)
free base sulphate
H - 1' 5.12 5.92
H - 1" 5.04 5.14
H - 5" eq 4.02 4.04
H - 5" ax 3.28 3.50




Figure 22. PMR spectrum of gentamicin base mixture
ppm
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Figures 23, 24 and 25 show NMR spectra of gentamicin C^, 
and respectively and Table 10 shows the allocation of 
chemical shifts according to a study by Morton et al. (103)
The differences in chemical shifts between gentamicin free base 
mixture and its sulphate salt are shown in the Figure 26 and Table 
11.
68.
Figure 23. NMR spectrum of gentamicin
>f 0
100 80 60 40 20 O
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Figure 24. NMR spectrum of gentamicin C,
100 80 60 40 20 O
ppm
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Figure 25. NMR spectrum of gentamicin C
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Trahie 10. ^^C-chemical shifts of gentamicin C and C
1 2  la
H3CHN
6 OH





















1 52.00 51.8 51.90 51.8 51.84 51.7
2 37.10 36.8 37.00 36.7 36.84 36.7
3 50.98 50.9 50.87 50.8 50.81 50.6
4 88.63 • 88.6 88.68 88.7 88.25 88.3
5 75.74 75.4 75.73 75.3 75.90 75.4
6 88.20 87.9 88.08 87.7 87.60 87.8
1' 102.93 102.6 102.82 102.6 101.63 102.2
2 ’ 51.30 51.1 51.20 51.0 51.35 51.0
3' 27.46 27.2 27.14 27.0 26.16 27.1
4' 26.32 26.1 26.27 26.0 28.33 28.5
5' 73.02 72.8 74.49 74.4 70.16 71.5
6' 58.61 58.2 50.49 50.3 45.40 46.1
7' 15.00 15.0 18.79 19.0
8 ’ 33.80 33.7
1" 101.68 101.4 101.57 101.3 100.82 101.3
2" 70.64 70.3 70.59 70.2 69.61 70.2
3" 64.73 64.5 64.68 64.4 64.84 64.4
4" 73.68 73.3 73.62 73.2 73.24 73.3
5" 69.07 68.7 69,01 68.7 69.01 68.7
6" 23.07 22.9 22.97 22.8 22.91 23.0
7" 38.24 38.1 38.14 38.1 37.87 38.0
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Figure 26. NMR spectrum of gentamicin base mixture.
100 80 60 40 20
ppm
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Figure 26. (contd.) NMR spectrum of gentamicin sulphate mixture.
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4 88.84(C ), 88.35 84.47
5 75.80 76.61
6 88.20 84.47
1' 102.98(C ),102.71(0 ) , 
102.44(C^^)
95. 35
2' 51.25 49. 57
3' 27.25 24.39
4' 26.22 (C^&Cg), 28.76(C^^) 28.62
5* 74.70(C ),72.75(C ), 74.97(0^),69.87(02),
71-72 (Cia/ 69.37(0^^)
6' 58.67(C^),50.54(02), 58.24(C^), 49.57(02),
46.26(0^^) 43.62(0^^)











Figure 27 shows the isobutane chemical ionisation spectrum 
of compound CXg. The ^  + hJ quasimolecular ion appears at 
m/e 322. The base peak at m/e 163 suggests the presence of a 
2-deoxystreptamine moiety whilst the peak at m/e 110 might 





The garosamine unit gives a peak at m/e 160 and the peak at 
m/e 129 may be due to loss of methylamine from this.
The 'H-NMR spectrum of CX^ (Figure 28) supports a bicylic 
deoxystreptamine-garosamine ring structure from CX^. Prominent 
singlets at 61.3 and 62.85 may be respectively the C-CH^ and 
NH-CHg of garosamine. These peaks have similar chemical shifts 
to those observed in gentamicin sulphate which suggests that this 
sample is ionised; perhaps as its carbonate salt.
Only one anomeric proton (1") is present as a doublet at 
65.00. Other ring proton resonances between 62.00 and 65.00 
resemble those in the spectra of gentamicin C.
Table 12 shows possible assignments based on the corresponding 

















































Figure 29 shows a spectrum of compound CX^ and Figure 30
shows a possible structure and the assignment of chemical 
shifts conpared with literature values (187 - 196) for 1-methyl 
garosamine and 2-deoxystreptamine (103).
The assignment of identical chemical shifts to carbon atoms 
1 and 3 and to 4 and 6 suggests that the 2-deoxystreptamine moiety 
is symmetrical and that the glycosidic link may be between the 
garosamine and the 5 position of the 2-deoxystreptamine instead 
of to the 6 position of 2-deoxystreptamine ring as in 
the major gentamicin C. components.
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Figure 29. spectrum of compound CX
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Figure 31 shows the chemical ionisation mass spectrum of 
compound CX^. The 1^1 + hJ quasimolecular ion and the fragmentation 
patterns are similar to those of compound CX .
The NMR spectrum of CX^ (Figure 32) is also similar to that 
of compound CX^.
The ^^C NMR spectrum of CX^ (Figure 33) is much more complex than 
that of CX^ and the sample may have been a mixture.
Berdy et al. (166) isolated one compound of M.W. 321 from 
the crude fermentation broth and identified it as garamine (Figure 
31). Of the two compounds with M.W. 321 isolated in this study 
the l^C NMR spectrum of CX^ suggests that the pseudodisaccharide 
may have a 1", 5 glycosidic bond. Thus CX^ may be garamine. The 
^^C NMR spectrum of CX^ does contain peaks consistent with this 
structure (Figure 34) though this leaves prominent peaks with 






































Figure 32. PMR spectrum of compound CX^
ppm
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Figure 33. NMR spectrum of compound CX
100 80 60 40 20
ppm
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Figure 34. A possible structure and the assignment of chemical
shifts compared with the literature values.
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Figures 35 and 36 show electron impact and chemical 
ionisation mass spectra of compound CX^. They show similar frag­
mentation patterns.
The peak at m/e 445 is assumed by analogy with gentamicin C 
to be a + H quasimolecular ion, implying a molecular weight 
of 444. Peaks at 322, 163 and 160 corresponding to garamine, 
2-deoxytreptamine and garosamine moieties respectively suggest 
that this compound differs from the major components of gentamicin 
in its A (purpurosamine) ring. In their study of minor components 
from the fermentation broth, Berdy e^ al. (166) isolated a compound 
of M.W. 444 to which they allocated to structure in Figure 37 
but gave no further details of its spectroscopic characteristics. 































































































In the ^H-NMR spectrum (Figure 38) the peak at 62.21 may 
represent the C-7'methyl group of the compound whilst peaks at 
61.29 and 62.73 may be due to the C-methyl and N-methyl groups 
of garosamine. Other resonances may be allocated as in Table 13.







Figure 38. PMR Spectrum of compound C'A
ppm
92
Figure 39. C NMR spectrum of compound CX,
loo 80 60 40 20 O
ppm
93,
The NMR spectrum shown in Figure 39 also seems to 





























The field desorption mass spectrum (Figure 41) of this 
compound gave an ion of m/e 496 and the chemical ionisation spectrum 
(Figure 42) one at m/e 495. This may imply that m/e 495 is 
a true and that m/e 496 is [m  + r]+ . The electron impact 
mass spectrum showed no peak higher than m/e 258 suggesting that 
this compound is particularly unstable. This conclusion is 
supported by the appearance of fragment ions at m/e 450, 322 and 249 
in the field desorption mass spectrum and by the relatively low 
m/e 496 ion in the chemical ionisation mass spectrum. In this 
latter spectrum the ions at m/e 322, 163 and 160 suggest garamine,
2-deoxystreptamine and garosamine moieties respectively. The 
peak at m/e 336 may represent the A and B rings. Berdy e^ al.
(116) isolated a compound with molecular weight 495 from the 
fermentation broth and assigned the structure shown in Figure 









































































Berdy et al. (165)
HjCHN OH OH
13 (M.W. 495) isolated by




The H-NMR spectrum (Figure 44) showed prominent peaks at 
62.97 and 61.37 which may be the -NK-CH^ and C-CH^ respectively of 
garosamine. A doublet centred at 61.20 may be a secondary C-methyl 
group as shown in the structure. The compound appears to be 
ionised since the resonances of the anomeric protons appear at 
















Figure 45 shows C spectrum of compound CX^ and Figure 46 shows 


























These chemical shifts are comparable with those of the salt 




This compound was recovered in very low yield, frequently 
contaminated with gentamicin C^. The chemical ionisation mass 
spectrum (Figure 47) gave a peak at m/e 489. No useful NMR 














































Figures 48 and 49 show chemical ionisation and field desorption 
spectra of this compound. They suggest that CX^ may be a mixture 
of compounds giving [m + peaks of 474, 460 and 446 and differing 
in their degree of méthylation plus a compound with |m + hJ of 
486. It is noteworthy that there is no peak at m/e 322 in the 
chemical ionisation spectrum suggesting that the bicyclic unit of 
this compound is different from that of the compounds previously 
described. The peak at m/e 160 in the chemical ionisation 
spectrum suggests the presence of a garosamine unit. If so the 
2-deoxystreptamine ring is absent. The peak at m/e 157 suggests 
an 'A' ring of the same type as gentamicin C^
Insufficient material was available for ^^C spectrum. The 
^H-NMR spectrum (Figure 50) is rather 'noisy' but shows peaks 















































































Figure 51 shows the chemical ionisation mass spectrum of 
compound CX^. It suggests a mixture of compounds differing in their 
degree of méthylation. The lack of a peak at m/e 322, the very 
prominent peak at m/e 290 and the peaks at m/e 160 (garosamine moiety), 
m/e 157 and m/e 143 (A rings of gentamicin and gentamicin 
respectively) all suggest that these compounds differ from the 
gentamicins in having a B ring which is not 2-deoxystreptamine.
Thus this mixture appears to be related to CX^ and may indeed have 





































Analytical methods based on the amino 
groups of gentamicin
Introduction
As an approach to the assay of gentamicin a number of anal­
ytical procedures for estimating the amino groups were examined. 
Experiments were carried out to determine the usefulness of:
1) Titration with acid
2) Derivatisation of the primary amino group with various 
fluorophores followed by fluorometric assay.
Fluoresence is a phenomenon whereby certain compounds are 
being irradiated with electromagnetic radiation of a specific 
wavelength, subsequently re-emit radiation of a longer wavelength.
On absorbing radiant energy molecules are excited to a higher 
electronic state, and must lose this excess energy in order to 
return to the ground electronic state (197, 198, 199). Re­
emission of energy as fluorescence occurs in compounds in which 
the electron system is shielded in some way from other de-activa­
tion processes such as internal conversion, collision or chemical 
reaction (200). Such a molecule, on excitation, may possess 
higher vibrational energy in the excited state than it possessed 
in the ground state. This vibrational energy is lost by collisional 
processes in the higher electronic state after which the molecule 
fluoresces, i.e. it drops back to the ground state with the emission 
of energy as radiation. The potential energy diagram (Figure 52) 
shows that the fluorescence energy is less than the incident 













Fluorimetric methods are inherently applicable to lower 
concentration ranges than are spectrophotometric determinations 
and are thus among the most sensitive available analytical 
techniques. The basic difference in the sensitivity between the 
two methods arises from the fact that the concentration-related 
parameter for fluorimetry (intensity of fluorescence) can be 
measured independently of the power of the beam incident upon 
the solution (Po). In contrast, a spectrophotometric measure- . 
ment is dependent upon the ratio between the intensities of 
incident (Po)and transmitted light (P). Thus the sensitivity 
of a fluorimetric method can be improved by increasing power 
of incident light (Po) as by further amplifying the fluorescent 
signal. In spectrophotometry, an increase in Po results in a 
proportionate change in P and thus does not alter the ratio 
between them. Thus no improvement of the detector signal 
results in no net gain with respect to absorbance value. Thus, 
fluorimetric methods generally have sensitivities that are 
two to four orders of magnitude better than the corresponding 
spectrophotometric procedures.
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Since the excitation and emission wavelengths are 
characteristic of a compound, this method also provides specificity. 
Fluorimetry, however, is less widely applicable than absorption 
methods because of the relatively limited number of chemical 
compounds that can be made to fluoresce.
Gentamicin C itself absorbs poorly in ultra-violet or visible 
regions of the electromagnetic spectrum,and spectrophotometry is 
not applicable for the detection of therapeutic concentrations 
of the drug in formulations and serum. However gentamicin 
possesses several primary amino groups and a fluorophase can be 
attached readily to these groups to yield fluorescent derivatives 
(94, 106).
In this study ortho-phthalaldehyde, fluorescamine and acetyl- 
acetone with formaldehyde were used for derivatisation of 












Acetylacetone with formaldehyde (153)
P  9













C H -C -C H 3
II








2-Mercaptoethanol, 0-phthalaldehyde, boric acid, potassium 
hydroxide, phosphoric acid, sodium hydroxide, hydrochloric acid, 
glucosamine and glycine were obtained from BDH Chemicals Limited, 
Methanol, acetone, formaldehyde and acetic acid were obtained 
from Fisons Scientific Apparatus Limited. Fluorescamine was 
manufactured by Sigma Chemical Conpany and acetyl acetone was 
obtained from Aldrich Chemical Company Limited.
Instruments
For titration - pH meter (EIL Model 7050)
For fluorescence analysis - Aminco Fluoro-Colorimeter
- Model 204A Perkin Elmer
Fluorescence Spectrophotometer.
Methods
3.1 Titration of gentamicin with 0.01 N hydrochloric acid 
Approximately 10 mg of gentamicin base mixture was accurately
weighed arid dissolved in water free of carbon dioxide. The 
solution was titrated with O.Ol N HCl and the pH was recorded 
until an obvious excess of HCl had been added.
3.2 Fluorimetric analysis of gentamicin 
3.2.1 Using Fluorescamine derivatives (201)
Preparation of fluorescamine solution
Fluorescamine (10 mg) was weighed and dissolved in 
acetone (50 ml).
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Preparation of borate buffer
0.2 M boric acid solution was adjusted to pH 8.7 with 
1 N sodium hydroxide solution.
Preparation of glycine solution
In this experiment glycine was examined as a possible 
standard. Glycine (8 mg) was accurately weighed and dissolved 
in water (lOOO ml) to give a concentration of 8 yg/ml. This 
was used to prepare a series of standard solutions of final con­
centrations of 0.8, 1.6, 2.4 and 3.2 yg/ml. Each solution was 
made up to 2.0 ml with water then 2.0 ml of borate buffer and
1.0 ml of fluorescamine solution added.
A blank was prepared by mixing 2.0 ml water, 2.0 ml of 
borate buffer and 1.0 ml of fluorescamine solution.
Preparation of gentamicin solution
Gentamicin C (4 mg) was accurately weighed and made 
up to 500 ml with water to give a concentration of 8 yg/ml.
1.0 ml of this solution was used, 1.0 ml water, 2.0 ml of borate 
buffer and 1.0 ml of fluorescamine solution were added.
In all cases, after addition of buffer, the tubes were 
rapidly shaken before addition of fluorescamine solution.
3.2.2. Using 0-phthalaldehyde derivatives (115)
Preparation of 0-phthalaldehyde reagent
Boric acid (1 g) was dissolved in water ( 38 ml) 
and adjusted to pH 10.4 with potassium hydroxide solution (450 g/ 
litre). 0-phthalaldehyde (200 mg) dissolved in methanol (2 ml)
116,
and 2-mercaptoethanol (0.4 ml) were then added to the borate 
buffer solution. The 0-phthalaldehyde reagent could be stored 
under nitrogen at 4 c for at least five days without significant 
change in the fluorescence yield of gentamicin. The reagent was 
prepared freshly each week.
Preparation of gentamicin solutions and glucosamine solution 
Gentamicin
A 0.1 mg/ml solution in water was prepared. 0.1 ml of this 
solution was diluted with 8.9 ml water and 1.0 ml OPA reagent 
added to give a final concentration of gentamicin of 1 yg/ml. 
The reaction mixture was kept in the dark for 1 hour at 20°C.
Gentamicin and
A 0.02 mg/ml stock solution of each was used. 0.5 ml of the 
stock solution was diluted with 8.5 ml of water and 1.0 ml OPA 
reagent added.
Glucosamine
Glucosamine was used as a standard in this experiment. A 
0.08 mg/ml stock solution was used to prepare a series of standard 
solutions of final concentrations of 0.8, 1.6, 2.4, 3.2, 4.0,
4.8, 5.6, 6.4, 7.2, 8.0, 8.8, 9.6, 10.4, 11.2 and 12.0 yg/ml.
Each solution was made up to 9.0 ml with water and 1.0 ml of OPA 
reagent added.
A blank was prepared by using OPA (1 ml) reagent and water 
(9 ml).
117.
3.2.3. Derivatisation of gentamicin with acetyl acetone and 
formaldehyde (153)
Preparation of Button-Robinson buffer (pH 2.6)
Solution I
Boric acid (6.183 g), acetic acid (5.73 ml) and phosphoric 
acid (5.6 ml) were mixed and the solution made up to 500 ml with 
water.
Solution II
1.0 M sodium hydroxide solution:
15 ml solution II was added to 100 ml solution I to give a 
final pH of 2.6.
Preparation of derivatising agent
Acetylacetone (0.8 ml) and formaldehyde (2.0 ml) were 
added to 10 ml of the buffer and the volume made up to 30 ml with 
buffer.
Preparation of derivative
A 4 ml sample of gentamicin (2 yg/ml) in water) and 
4 ml of derivatising agent were mixed and heated for 10 minutes 
at 100°C.The tube was cooled and excitation and emission spectra 
were recorded.
Results and discussion
(1) Titration of gentamicin with 0.01 N hydrochloric acid
Figure 54 shews the titration curve of gentamicin base mixture 
with 0.01 N HCl. It can be seen that the end point was not sharp.















HCl added. Using this method, the amount of gentamicin in the 
sample was 92% of the weight taken (average of three determinations)
It was concluded that this method is not suitable for the 
routine analysis of gentamicin because of the difficulties in 
determining the end point and the rather low result for the 
concentration.
(2) Fluorimetric analysis of gentamicin
2.1 Fluorescamine derivative
The excitation and emission maxima of the fluorescamine 
derivatives of gentamicin and glycine are summarised in Table 14 











The excitation and emission spectra of gentamicin C 
are shown in Figures 55 and 56. The spectra for gentamicins C 
and Cl and the standard glucosamine were identical to these.
The calibration graph of fluorescence intensity against 








































































































































The fluorescence intensities of the sample solutions were 
measured and the equivalent concentrations were read off from 
the calibration graph.
Assuming that all the primary amino groups are derivatised 
the equivalent weights of gentamicin and are 159,
112.25, and 115.75 respectively.
Table 15 shows the results obtained when known samples of 
each gentamicin component were assayed by this method. Each value 


















It is clear that this method grossly overestimates the con­
centration of gentamicin.
The measured fluorescence intensity of a substance is given 
by the equation: (198, 200, 203)
F = K. $ . I . E . c. d 
o
where F = fluorescence intensity
$ = quantum yield of fluoresence
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K = constant of compounds at wavelength of measurement 
I^= intensity of incident light 
E = molar absorption coefficient 
c = concentration 
d = pathlength
In any assay in which the standard and sample are the same 
compound, most of these terms will be constant and fluorescence 
intensity is proportional to concentration within certain conc­
entration ranges.
In this experiment in which gentamicin was compared with a 
model compound,glucosamine, $, K or e may be different and thus 
affect the fluorescence intensity.
2.3 Lutidine derivative
The excitation and emission spectra of gentamicin 
































































































Microbiological assays and the biological 
activity of the gentamicin components
Introduction
The microbiological assay used was an agar well diffusion 
method similar to that of the B.P. 1980 (185). In this method 
the substance to be assayed is allowed to diffuse through a 
solid culture medium inoculated with a susceptible organism.
If the substance being assayed is a bactericidal agent a zone 
of inhibition of growth is observed. The size of the inhibition 
zone is a function of the concentration of the antimicrobial 
agent. This function can be expressed as a linear relationship 
between the size of the zone and the logarithm of the concentration 
of the substance. By measuring the diameter of the zone 
produced by an unknown sample and comparing it with that of a 
known standard preparation, the potency of the unknown sample 
may be calculated (204).
The advantages of diffusion type assays are: (205)
1) The method allows for more rigid control of conditions than 
turbidimetric methods, giving an assay of greater precision. 
The probable error can be readily calculated and the 
accuracy increased by the inclusion of sufficient replicates.
2) The testing of several samples on the same culture surface 
increases uniformity.
3) Samples need not be sterile. This prevents possible loss 
of activity from sterilisation procedures.
4) The presence of high concentrations of organic solvents can 
be tolerated by the use of suitable controls.
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5) The method is readily automated and adapted for large scale 
routine analysis (207, 208).
The disadvantages are:
1) The method is relatively insensitive when compared with 
other methods of assay.
2) The method is limited to those substances which diffuse 
readily in agar. The activity of a substance is measured 
only to the extent of the diffusion before multiplication 
of the organism.
3) There may be a lack of definition of zones due to the 
geometry of radial diffusion.
4) The method can only be used for the ccomparison of samples 
of the same or closely related substances.
5) The method cannot be used for unknown substances until a 
standard has been established.
The method employed here is a cup plate method whereby the 
agar is allowed to harden and a slug is removed by means of a 
sterile cork borer. The size of the cork borer is optional.
In employing this method, there are several factors which are 
important if accurate and reprodubible results are to be obtained. 
The cups must be cut vertically, and must be completely filled with 
the solution being assayed. The optimum thickness of the agar 
is 5 to 6 mm (209).
This method was used:
1) To determine the potency of a series of commercial genta­
micin samples from a variety of geographical sources.
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2) To determine the potency of a series of formulations con­
taining gentamicin.
3) To compare the potencies of each of the components of 
commercial gentamicin isolated by column chromatography 
with the activity of the whole mixture.
Materials and Methods
Gentamicin sulphate was donated by Nicholas Laboratories 
Ltd. Sensitivity test agar (Lab m) was obtained from London 
Analytical and Bacteriological Media Ltd. Membrane filters 
were obtained from V.A. Howe and Co. Ltd.
4.1 Preparation of gentamicin solutions
Commercial samples of gentamicin sulphate were dried at llO^C 
for 2 hours and allowed to cool in a vacuum de siccator over 
silica gel. Each was dissolved in sterile distilled water to 
give a stock solution equivalent to lOO yg/ml of gentamicin 
base allowing for the sulphate content. A series of solutions 
were prepared to give final concentrations of 20, 10, 5, 2.5 and 
1.25 yg/ml.
All the solutions were filtered through a membrane filter 
(pore size 0.45 y) before transfer into the wells.
For the gentamicin-containing formulations the basic 
methods were modified slightly to control the effects of ex­




1 ml of injection contains:
Gentamicin sulphate equivalent to gentamicin base 40 mg 
methylhydroxybenzoate B.P. 1.8 mg
propyl hydroxybenzoate B.P. 0.2 mg
sodium metabisulphite B.P. 3.2 mg
disodium edetate B.P. 0.1 mg
5 ml of injection was diluted with sterile distilled water 
to a concentration equivalent to 100 yg/ml of gentamicin base.
A series of solutions were prepared from this stock solution to 
give concentrations of 20, 10, 5, 2.5 and 1.25 yg/ml.
At the highest concentration of gentamicin, the concentrations 
of other ingredients were as follows.
methyl hydroxybenzoate B.P. 0.9 yg/ml
propyl hydroxybenzoate B.P. 0.1 yg/ml
sodium metabisulphite B.P. 1.6 yg/ml
disodium edetate B.P. 0.05 yg/ml
Another stock solution was prepared containing these con­
centrations of the other ingredients. This was used as a control 
solution.
The control wells were divided into two parts, three being 
filled with sterile distilled water and another three with the 
solution prepared above.
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4.1.2 Gentamicin Paediatric 
1 ml contains :
gentamicin sulphate équivalent to gentamicin base 10 mg
methylhydroxybenzoate B.P. 1.3 mg
propylhydroxybenzoate B.P. 0.2 mg
sodium metabisulphite B.P. 3.2 mg
disodium edetate B.P. 0.1 mg
1 ml of injection was taken and diluted to 100 ml with 
water. This was a stock solution at a concentration of lOO yg/ml 
of gentamicin base. A series of solutions were prepared as in
gentamicin injection. The control solution was prepared in
the same way and contained:
methylhydroxybenzoate B.P. 2.5 yg/ml
propylhydroxybenzoate B.P. 0.4 yg/ml
sodium metabisulphite B.P. 6.4 yg/ml
disodium edetate B.P. 0.2 yg/ml
4.1.3 Gentamicin intrathecal 
1 ml contains:
gentamicin sulphate equivalent to gentamicin base 1 mg
sodium chloride 8.5 mg
5 ml of the preparation was taken and diluted to 50 ml with
water. A series of solutions at the same concentration as in (1) 
were prepared. For the control sodium chloride (8.5 mg) was 
accurately weighed and dissolved in sterile distilled water.
The solution was made up to 50 - ml.
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4.1.4 Gentamicin/Hydrocortisone
Ear drops containing gentamicin sulphate equivalent to 
gentamicin base 0.3% w/v and hydrocortisone acetate 1%.
3.5 ml of the solution was taken and diluted to 100 ml with 
water. A series of solutions at the same concentration as in (1) 
were prepared. The solutions were passed through membrane 
filters, to yield clear filtrates.
4.1.5 Gentamicin Eye/Ear drops 
100 ml of solution contains:
gentamicin sulphate equivalent to gentamicin base 0.3 g 
benzalkonium chloride 0.04 g
3.5 ml of the preparation was taken and diluted to 100 ml 
with water. A series of solutions at various concentrations 
were prepared in the same way as (1). For the control, a 
0.00028 g/lOO ml solution of benzalkonium chloride was prepared.
4.1.6 Gentamicin Ointment
100 g of ointment contains gentamicin sulphate equivalent 
to gentamicin base 0.3 g in an anhydrous greasy basis.
The extraction method was as described in British Pharma­
ceutical Codex (1973) (221). Ointment (3.5 g) was accurately
weighed and dissolved in chloroform (20 N). The solution was 
extracted with 0.2 M phosphate buffer, pH 8.0 (4 x 20 ml).
The extracts were combined and the solution was made up to 100 ml 
with 0.2 M phosphate buffer, pH 8.0. A series of solutions at
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various concentrations was prepared in the same way as (1). 
Chloroform vapour was removed by passing a stream of air through 
the solution. For the control, 0.2 M phosphate buffer pH 8.0 
(20 ml) was taken and diluted to lOO ml with water.
4.2 Preparation of the plate
Agar (8 g) was weighed and placed in a bottle. Water (200 
ml) was added and the mixture autoclaved at a pressure of 
15 lbs/in^ and 121°C for 15 minutes. The agar was cooled to 
about 50°C then 5 ml of a suspension of Bacillus pumilus NCTC 
8241 (concentration of spores 10 x 106 to lOO x lO^ per ml in 
water) were added before pouring into the plate. The plate was 
allowed to set and dried at 37°C for 30 minutes. Wells were 
punched using a No. 5 cork borer (about 9 mm diameter) and a 
template to aid positioning of the wells.
The standard and test solutions were transferred into the 
wells using a lOO yl automatic pipette (Transferpette , Rudolf 
Brand, 698 Wertheim, West Germany) according to a Latin square 
randomisation (Figure 60).
c D E F A B
D E F A B C
E F A B C D
F A B C D E
A 8 C D E F
B C D E F A
A, B, C, D, E and F represent concentrations of 20, lO, 5,
2.5, 1.25 yg/ml and control (sterile distilled water) respectively.
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The plates were allowed to diffuse for 2 hours at room 
temperature and then incubated at 37°C for 12 hours. The inhi­
bition zone around each cup was measured by vernier caliper and 
a graph of log concentration against mean zone diameter was 
plotted. A fresh response curve was prepared each day using 
a sample of gentamicin B.P. (Batch Number 80501) obtained from 
Nicholas Laboratories as the standard.
The potencies of the unknown samples were calculated by 
reference to the appropriate standard response curve. Six 
replicates at each of five concentrations were carried out for 
both standards and unknowns.
Results and Discussion
Table 16 shows inhibition zone diameters for the standards 
and unknown samples.
It is clear that considerable day to day variation in the 
inhibition zone size occurs for the standard solutions, emphasising 
the need for the construction of fresh response curves each day. 
Figure 61 shows a typical calibration graph of log gentamicin 
concentration against zone diameter. Table 17 shows the potency 
of the commercial samples of gentamicin expressed as a percentage 
of the weight taken.
For all the samples these results were within the limit 
required by the B.P. 1980.
Table 18 shows the potency of the formulations as a percentage 
of the amount shown on the label.
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Table 15 shows the relationship between zone diameter (in mm) 
and log concentration of gentamicin (in pg/ml).
Sample average inhibition zone diameter (mm) 
concentration (yg/ml)
20 10 5 2.5 1.25
at each 
Control
Gentamicin mixture 24.69 22.61 20.59 18.47 15.68 .
gentamicin 24.77 22.75 20.70 18.67 15.51 -
gentamicin 25.45 23.58 21.66 19.57 16.80 -
gentamicin C 26.10 2 4. 05 22.06 20.03 17.48 -
cx ® 22.57 20.52 18.42 15.59 - -
cx" 19.82 17.72 15.72 - - -
cx" 17.78 15.81 13.12 11.39 - -
“ 4 19.86 18.16 16.44 14.42 12.41
-
cx| 25.51 23.68 21.95 20.22 17.92 -
cx! 12.08 - - - - -
cx^ 19.83 17.51 14.29 12.27 - -
17.33 15.39 11.26 - - -
standard 2 25.28 23.52 21.70 19.00 15.70 —
Pierrel 061 25.24 23.62 21.75 . 18.90 15.64 -
Sample (2) 24.83 23.39 21.49 18.86 15.70 -
Chinese 24.87 23.42 21.46 18.82 15.68 -
Standard 3 25.11 23.52 21.33 18.87 15.93 -
SZ—GMC— 8~L~ 8 24.69 23.44 21.39 18.82 16.00 -
Pierrel 067 24.81 23.25 21.22 18.83 15.69 -
SZ-QIC-8-L-9 25.17 23.43 21.35 18.87 16.06 -
Standard 4 25.48 23.36 21.65 19.09 15.32 -
Pierrel 062 25.57 23.30 21.24 18.73 14.99 -
Pierrel 065 25.07 23.23 21.50 19.29 15.49 -
Pierrel 066 25.80 23.14 21.36 19.13 15.24 -
Standard 5 28.95 26.84 24.58 22.33 18.48 —
Pierrel 064 28.72 26.62 24.63 21.92 17.24 -
Standard 6 28.18 26.02 24.15 21.80 1.7.90 -
Hungarian 28.01 25.92 23.85 21.79 18.22 -
Standard 7 28.59 26.49 24.22 21.96 18.26 -
Italian 28.43 26.34 24.30 21.77 18.58 -
SZ-GMC-8-L-6 28.42 26.50 24.28 21.99 18.50 -










Standard 8 28.19 26.22 24.30 21.82 18.10 —
SZ-GMC-8-L-7 28.11 26.17 24.08 21.89 18.52 -
Sample (3) 28.22 26.07 24.14 21.47 18.33 -
Standard 9 28.47 26.31 24.29 21.88 18.06 —
Sample (4) 28.35 26.25 24.28 22.07 18.28 -
Sample (1) 28.50 26.40 24.17 21.59 18.06 -
Standard 9 25.23 23.37 21.55 18.86 15.86 —
'Genticin injection' 25.21 23.77 21.72 18.72 15.47 -
'Paediatric
injection' 25.26 23.46 21.58 18.48 16.05 -
Standard 10 25.11 23.29 21.45 18.75 16.12 -
'Genticin Eye/Ear
drops' 25.17 23.33 21.58 18.91 16.13 -
'Gentisone' 25.08 23.35 21.45 18.88 15.92 -
'Gentamicin
ointment' 24.98 23.18 21.26 18.64 15.82 -
Standard 11 24.76 22.66 20.55 18.56 15.76 -
'Genticin intra­
thecal ' 25.86 24.32 23.19 ,22.07 19.68 13.53
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Pierrel 061 100.5 3.78
Pierrel 062 97.7 1.99
Pierrel 064 93.3 5.35
Pierrel 065 99.9 8.52
Pierrel 066 101.8 6.81





Sample 1 99.0 4.28
Sample 2 96.1 7.19
Sample 3 96.5 5.13







Sample percentage potency coefficient
of
variation
Gentamicin injection 101.3 7.56
Gentamicin paediatric 101.3 6.48
Gentamicin Eye/Ear drops 104.2 5.47
Gentamicin/Hydrocortisone 102 .3 4.23
Gentamicin ointment 98.9 3.25
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The saline controls for 'gentamicin intrathecal' were 
themselves found to inhibit bacterial growth (Table 16). and 
a plot of inhibition zone diameter against log concentration 
for this material was not parallel to that of the standard 
(Figure 62). Thus this method is not suitable for the assay 
of gentamicin in this formulation.
This agar diffusion method was also used to compare the 
antimicrobial activities of the components of gentamicin C 
isolated as described in Chapter 2.
Figure 63 shows plots of inhibition zone size against log 
concentration for both major and minor components. They are 
compared with a plot for gentamicin mixture in its base form.
It can be seen that the major components have similar but 
slightly higher activity than the gentamicin mixture. This 
may reflect the fact that except for compound CX^ the minor 
components have much lower microbiological activity and 
therefore the total activity of the mixture is reduced in the 
presence of minor components.
However, the graph also shows that some of the minor 
components do possess antimicrobial activity.
Some of these minor components may be structurally related 
to the compounds isolated from crude fermentation broths by 


























against Bacillus subtilis. The three minor components isolated 
by the method of Thomas and Tappin (151) did not show anti­
microbial activity against this same organism.
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CHAPTER 5
High performance liquid chromatographic analysis 
of gentamicin
Introduction
HPLC is a development of classical liquid chromatography in 
which the introduction of high-pressure pumps allows rapid flow 
rates and the use of small particle column packing materials with 
high efficiency. The basic equipment is shown schematically in 
Figure 64 and consists of a high pressure pump, an injection port 
a column and a detector. The detector signal is recorded on a 
chart strip recorder (210, 211). '
injection port








There are two basic types of pump in common use: constant 
pressure pumps and constant volume pumps (212-215).
If a constant volume pump is used, changes in the pressure 
characteristics of the system, caused by settling or swelling of 
the packing, or viscosity changes in the mobile phase(caused either 
by temperature fluctuations or by composition changes) manifest 
themselves as changes in the pressure rather than in the flow rate. 
Because flow changes cause non-producible retention times, ad - 
versely affect resolution, and give unstable base-lines, the 
constant volume pump provides a more precise analysis. There are 
two main types of constant volume pumps: constant displacement,
(syringe type) pumps and the reciprocating piston or diaphragm 
pumps. The former are pulse free, whereas the latter type requires 
pulsation dampening for detector stability.
Constant pressure pumps, consisting of scxne form of pneumatic 
device for the direct pressurization of the mobile phase with 
an inert gas, give a reliable pulse-free flow and have the advan­
tage of low cost and simplicity. They are however not as accurate 
as constant volume pumps but can be used where flow accuracy 
and reproducibility are less critical.
Columns
Columns for HPLC vary depending primarily on the type of 
separation desired and the physical characteristics of the packing 
materials. Analytical columns have internal diameters of 2, 4 or
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6 mm and are precision base stainless steel. The column shape is 
usually straight; however, with slurry packing techniques, 
bent or coiled columns have been shown to be equally efficient 
(216).
Column packings for HPLC consist of either porous layer 
beads (30 - 40 ym) or microparticulate packings (5 - 10 ym). 
Because of their higher efficiency, sample capacity, and speed 
of analysis, microparticulate packings are now displacing the 
porous layer beads for general use.
Several adsorbents have been used as packing materials; 
silica, alumina, graphitized and non graphitized carbon blacks, 
carbon-coated silica gels, and styrene-divinyl benzene copolymers 
(217). Alumina has some selectivity advantages in the analysis 
of hydrocarbons and halogen-containing compounds and is useful for 
highly basic compounds (218). At higher pH values alumina is 
more stable than silica (219).
It is possible to attach either non polar or polar groups 
to the hydroxyl groups on the silica surface. Thus bonded phases 
can be used in "normal", reversed-phase, or ion-exchange chroma­
tography. The polarity of the bonded phase packings can vary 
from hydrophobic octadecylsilane to the ionic phases used in ion- 
exchange chromatography, fmong the non polar bonded phases used 
in reversed-phase liquid chromatography, there are essentially 
four different types of bonds between the silica surface and 
the organic moiety attached to it (217):
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\
(1) -^Si - OR Ester type
\
(2) -^Si - NR^ Amino type
\
(3) - Si - CR^ Carbon type
\
(4) - Si - O - Si - CR Siloxane type
/ ^
R is usually an ethyl, octyl, or octyldecyl (CDS) group.
The shape and size distribution of commercial packings can 
vary from irregular to spherical particles. Both types give 
similar plate counts; however, spherical particles are preferred 
because of their higher permeability.
Injection systems (216)
Samples are introduced by one of three methods.
(1) Syringe injection
On-column syringe injection leads to the highest separation 
efficiency. If specially designed syringes are used, syrin ge 
injections can be made up to pressures of at least 1500 psi; 
ordinary microlitre syringes as used in gas chromatography can 
often be used up to lOOO psi. Syringe injections can be made 
through a septum injector or using a septum-less system.
(2) "Stop-flow" Technique
In this technique solvent flow is momentarily stopped; column 
inlet pressure drops to atmospheric pressure; a sample is 
injected onto the top of the column; and solvent flow is resumed. 
Normal low pressure gas chromatography syringes are used. Sample
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diffusion in the solvent is so slow that resolution is unaffected.
(3) Sample valve
Valve injections are designed to operate at pressures in 
excess of 5000 psi without the use of septa. The solvent flow is 
by-passed into the column and an external or internal loop is 
filled with sample, which is then introduced into the column by 
switching a valve. The sample loops can either be external and 
interchangeable to give a range of volumes (10 to 500 yl), or 
internal and of fixed volume. Sample valves are the most convenient 
and reproducible method of sample injection.
Detection
Detection (and quantitation) of solutes in the column effluent 
can be performed by a variety of techniques including polarography, 
electrolytic conductivity, dielectric constant measurement, radio­
activity and mass spectrometry(212). However, the most commonly 
used detection systems employed for liquid chromatography are 
absorption of ultraviolet (UV) and visible li^t, refractive index 
determination and fluorescence.
Of these, the absorption of ultraviolet or visible light is 
the most widely used. A wavelength of 254 nm is commonly used 
since many biologically important compounds absorb strongly at 
this wavelength. Variable wavelength UV-visible spectrophotometers 
covering the UV and visible light spectrum are also available.
Where a solute has no absorption in this region of the spectrum
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it is often possible to prepare suitable derivatives either before 
(pre-colomn) or after (post column) the compound has been chroma­
tographed.
Measurement of refractive index is the second most popular 
detector system in liquid chromatography. The refractometer con­
tinuously monitors the difference in refractive index between the 
mobile phase and the mobile phase plus the sample as it elutes 
from the column (213). The major advantage of refractive index 
detection is versatility since they do not depend upon the 
presence of a chromophore. However, refractometers are generally 
less sensitive than UV-visible light detectors by two or more 
orders of magnitude (214) and are not suitable for gradient elution.
Fluorescence detectors can be employed for several classes
of compounds that possess natural fluorescence. Moreover, as
in spectrophotometric detection, fluorescent derivatives can be
prepared to detect compounds with no natural fluorescence. In
this latter case the greater sensitivity of fluorescence detection
often makes this preferable to attaching a UV or visible chromophore.
The energy source is UV radiation, which is passed through an
excitation filter for selection of the wavelength (s) at which the
sample will be excited (excitation maximum). After excitation,
the fluorescing sample emits energy at a longer wavelangth
(emission maximum). This energy is passed through an emission
filter which removes the unwanted radiation, and the remainder
is detected by a photomultiplier. The sensitivity of fluorimetry
-9
for strongly fluorescing compounds may approach 10 g/ml (213).
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Application of HPLC to antibiotics
HPLC ean be effectively implemented for the quantitation of 
antibiotics in body fluids. Necessary procedures for the assay 
include quantitative extraction from biological fluid, separation 
and accurate detection. The advantages of HPLC in the analyses 
of antibiotic in body fluids are (220):
(1) The wide choice of stationary phases and solvent systems 
available.
(2) Separations are performed within minutes and total assay 
time can be kept to a minimum.
(3) The method can be applied for studies of the pharmacokinetic 
behaviour of antibiotics.
Gentamicin has no absorption in UV or visible light, but does 
contain several primary amino groups to which a fluorophore can 
easily be attached. This provides a sensitive means of detection 
and by introducing lipophilic groups also allows separation by 
reversed-phase chromatography (107, 180, 179, 181, 177, 172,
182, 176). Two derivatising reagents, fluorescamine and 
0-phthalaldehyde were examined for suitability.
As stationary phase a monomolecular layer of octadecylsilane 
chemically bound to small particle silica gel was used. A variety 
of mobile phases were tested with the fluorescamine derivative.
For the OPA derivative the system of Maitra et al. (172), 
methanol and water containing tripotassium ethylene diamine 
tetraacetate was used.
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Materials and Methods 
Apparatus
Analyses were performed on a liquid chromatograph (Constametric 
I, Laboratory Data Control, Division of Milton Roy) equipped with 
a fluorescence spectrophotometer (Perkin-Elmer fluorescence 
spectrophotometer 204-S) detector. Separations were accomplished 
on a 10 cm X 4.0 mm i.d. reversed-phase column (Spherisorb S5 ODS, 
Phase Separations) maintained at 30 - O.2°C. Samples were injected 
by the use of a 25 yl loop (Spectroscope accessory company, Sidoup, 
Kent, England). The liquid chromatography detector was connected 
to a computing integrator for measurement of the chromatogram peak 
areas (Perkin-Elmer Sigma 10 Chranatography Data Station). Mobile 
phases were filtered using a membrane filter (pore size 0.45 y) 
(Satorius Membrane Filter, GMGH, 34 Gotinggen, West Germany).
Materials
Boric acid, sodium hydroxide, tetra butylammonium hydroxide, L- 
arginine monohydrochloride, trichloroacetic acid, ammonium 
sulphate, barium perchlorate, thorin indicator, sulphuric acid 
and perchloric acid were obtained from BDH Chemicals Limited. 
Acetone, ethanol and isopropanol were frcm Fisons Scientific 
Apparatus Limited. Fluorescamine and D-camphor-lO-sulphonic 
acid were from Sigma Chemical Company. Tripotassium ethylene 
diamine tetra acetate was obtained from Fluorochem Limited,
Glossop, Derbys. Gentamicin C^, C^ and C^^ were prepared by 
column chromatography as described in Chapter 2. All the 
components were pure when checked by thin-layer chromatography 
high-pressure liquid chromatography, nuclear magnetic resonance
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spectroscopy and field desorption mass spectrometry. Gentamicin 
was provided by Sobering Corporation Research Division. Water 
used was glass distilled and de-ionised.
Methods
5.1 HPLC of gentamicin using fluorescamine as derivatising agent
5.1.1 Chromatographic conditions and instrumental settings
Column Spherisorb S5 ODS,20cmx0.4cm i.d.
Injection volume 25 yl
Flow rate 1.8 ml/min
Excitation wavelength 397 nm
Emission wavelength 475 nm
Sensitivity varied according to each injection
PM gain 3
5.1.2 Preparation of mobile phase
12 different mobile phases were examined
(1) 100% methanol
(2) 80% methanol, 20% 0.1 M borate buffer pH 8.0
(3) 70% methanol, 30% 0.1 M borate buffer pH 8.0
(4) 60% methanol, 40% 0.1 M borate buffer pH 8.0
(5) 50% methanol, 50% 0.1 M borate buffer pH 8.0
(6) 40% methanol, 60% 0.1 M borate buffer pH 8.0
-4
(7) 60% methanol, 40% of 1 x 10 M eetyl dimethyl benzyl 
ammonium chloride solution
-4
(8) 55% methanol, 45% of 1 x 10 M ce.tyl dimethyl 
benzyl ammonium chloride solution.
(9) 60% methanol, 40% water and tetrabutylammonium 
hydroxide (TBA)(20 yg/ml)
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(10) 55% methanol, 45% water and TBA (20 yg/ml)
(11) 60% methanol, 40% of 0.01 M D-camphor-10-sulphonic 
acid adjusted to pH 4.0 with NaOH
(12) 30% acetonitrile, 70% water and TBA (15 yg/ml)
5.1.3 Preparation of fluorescamine solution
Fluorescamine (10 mg) was dissolved in acetone and the 
solution was made up to 50 ml with acetone.
5.1.4 Preparation of borate buffer
Boric acid (1.2366 g) was dissolved in water and the 
solution was made up to lOO ml with water. This solution was 
titrated with 1 N NaOH to a final pH of 8.7.
5.1.5 Preparation of derivatives
2 ml of a stock solution of each gentamicin C component 
(0.08 mg/ml) was mixed with 2 ml of borate buffer and then the 
fluorescamine solution was added with vigorous mixing. In most 
experiments 1 ml of fluorescamine was used but in one experiment 
concerned with the extent of reaction up to 8 ml was used.
5.2 HPLC of gentamicin using 0-phthalaldehyde as derivatising 
agent
5.2.1 Chromatographic conditions and instrumental settings 
Column: Sperisorb S5 ODS, 10 cm x 0.4 cm i.d.
The column was conditioned for 1 hour, with mobile phase. 
Injection volume 25 yl or 50 yl 
Flow rate 1.9 ml/min or 1.6 ml/min
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Excitation wavelength 345 nm
Emission wavelength 430 nm
Sensitivity varied according to concentration in each 
injection 
PM gain 3
5.2.2 Preparation of mobile phase
The mobile phase used was a mixture of methanol/water 
(79/21 by volume) containing 2 g of tripotassium ethylene diamine 
tetraacetate per litre. The mixture was passed through a membrane 
filter (pore size 0.45 y) and degassed prior to use.
5.2.3 Preparation of standard solutions
A series of standard aqueous solutions of gentamicin 
and were prepared to give final concentrations of 0.012,
0.02, 0.04, 0.048, 0.06,0.07 and 0.08 mg/ml.
An aqueous solution of L-arginine monohydrochloride (.0.0375 mg/ml) 
was used as internal standard.
5.2.4 Preparation of samples
(1) Commercial mixture of gentamicin sulphate
Gentamicin sulphate (3.5 mg) was accurately weighed 
and dissolved in 25 ml of distilled vater.
(2) Formulations
2.1 Gentamicin Injectable
Each 2 ml of solution contains:
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Gentamicin sulphate B.P. equivalent to gentamicin base 8.0 mg
Methylhydroxybenzoate B.P. 3.6 mg
Propyl hydroxybenzoate B.P. 0.4 mg
Sodium metabisulphite B.P. 6.4 mg
Sodium edetate B.P. 0.2 mg
Manufacturers: Nicholas Laboratories Limited 
Roussel Laboratories Limited 
Warrick Pharmaceuticals Limited
1 ml of injection was diluted to 100 ml with water. 0.1 ml of
this solution was taken for derivatisation.
2.2 Gentamicin Intrathecal
Each 1 ml of solution contains:
Gentamicin sulphate B.P. equivalent to gentamicin base 5 mg
Sodium chloride Ph.Eur. 8.5 mg
Manufacturers: Nicholas Laboratories Limited 
Roussel Laboratories Limited
2 ml of the preparation was taken and diluted to 10 ml with water.
0.1 ml was taken for derivatisation.
2.3 Gentamicin Eye/Ear drops
Eye/ear drops containing gentamicin sulphate B.P. 
equivalent to 0.3% w/v gentamicin base 
Manufacturer: Nicholas Laboratories Limited
1 ml of the preparation was taken and diluted to 10 ml with
water. 0.1 ml was taken for derivatisation.
2.4 Gentamicin/Hydrocortisone acetate Ear drops
Ear drops containing gentamicin sulphate B.P. equivalent
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to 0.3% w/v gentamicin base and 1.0% w/v 
Hydrocortisone acetate Ph.Eur.
Manufacturer: Nicholas Laboratories Limited 
1 ml of the preparation was taken and diluted to 10 ml with water. 
0.1 ml was taken for derivatisation.
2.5 Gentamicin cream
Containing gentamicin sulphate B.P. equivalent to 0.3% w/w 
gentamicin base.
Manufacturer: Nicholas Laboratories Limited.
Gentamicin cream (0.5 g) was accurately weighed and dispersed in 
100 ml water. A suspension of fine particles was formed. 0.55 ml 
of this suspension was taken for the derivatisation.
2.6 Gentamicin Ointment
Containing gentamicin sulphate B.P. equivalent to 0.3% 
w/w gentamicin base.
Manufactuer: Nicholas Laboratories Limited 
Roussel Laboratories Limited 
Ointment (0.5 g) was accurately weighed and dissolved as completely 
as possible in 20 ml of chloroform. The solution was extracted with 
three successive 20 ml portions of 0.2 M phosphate buffer pH 8.0. 
The combined extract was diluted to 100 ml with buffer (221).
0.55 ml of this solution was taken for derivatisation.
2.7 Gentamicin Paediatric Injection 
Each 1 ml contains:
Gentamicin sulphate B.P. equivalent to gentamicin base
10 mg
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Methyl hydroxybenzoate B.P. 1.3 mg
Propyl hydroxybenzoate B.P. 0.2 mg
Sodium edetate B.P. 0.1 mg
Sodium metabisulphite B.P. 3.2 mg
Manufacturers Warrick Pharmaceuticals Limited
Roussel Laboratories Limited 
1 ml of the preparation was taken and diluted to 25 ml with water.
0.1 ml of this solution was taken for derivatisation.
5.2.5 Preparation of 0-phthalaldehyde derivatising agent (172)
Boric acid (1 g) was dissolved in water (38 ml) and 
adjusted to pH 10.4 with potassium hydroxide solution (450 g/1). 
0-phthalaldehyde (200 mg dissolved in 2 ml of methanol) and 
2-mercaptoethanol (0.4 ml) were then added to the borate solution. 
The reagent was stored at 4°C and protected from light. New reagent
was freshly prepared each week.
5.2.6 Effect of storage time upon the stability of OPA derivatives
0.15 ml of gentamicin solution (0.08 mg/ml), 0.1 ml 
of arginine solution (0.0375 mg/ml), 0.4 ml water, 0.1 ml OPA and
5.0 ml ethanol were mixed.. The solution was filtered and 
stored in the dark. Injections were made at the intervals of 
10 minutes up to 315 minutes.
The stability of the arginine derivative in the light was 
also studied by using 0.1 ml arginine alone. The derivative was 
prepared as described above. Injections were made at the intervals 
of 5 minutes up to 305 minutes.
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5.2.7 Preparation of derivatives
(1) For calibration graph
0.22 ml of gentamicin 0.18 ml of gentamicin 0.15 ml 
of gentamicin and 0.1 ml of L-arginine monohydrochloride 
solutions were used in each tube. 0.1 ml of 0-phthalaldehyde 
reagent and 5.0 ml of ethanol were added. The solutions were 
filtered and kept in the dark for 1^ hours before injection.
(2) For samples
0.1 ml of L-arginine monohydrochloride solution was 
added to 0.55 ml of each sample (in the case of those formulations 
where only 0.1 ml of the preparation was used, 0.45 ml of water 
was added) and the mixture derivatised as described above.
(3) For plasma sample
3.1 Recovery when various precipitating agents were used
3.1.1 Control
1.0 ml of gentamicin sulphate solution (0.14 mg/ml) and
3.5 ml of water were mixed using a Vortex mixer. 1.0 ml of this 
solution was taken, 1.0 ml of OPA reagent and 2.0 ml of ethanol 
were added.
3.1.2 Using trichloroacetic acid (5% w/v) as precipitating agent
1.0 ml of gentamicin sulphate solution (0.14 mg/ml) 
and 0.5 ml of plasma were mixed using a Vortex mixer. 3.0 ml of 
trichloroacetic acid solution (5% w/v) was added and the mixture 
was centrifuged for 15 minutes. 1.0 ml of supernatant was taken.
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1.0 ml OPA reagent and 2.0 ml of ethanol were added. The per­
centage recovery of gentamicin was determined using a series of 
stock solutions containing 1, 2, 4, 6, 8, 10, 11 and 12 yg/ml 
of gentamicin. 1.0 ml of each solution was taken and diluted 
with 2.5 ml of water. 1.0 ml of each solution was mixed with
1.0 ml OPA reagent and 1.0 ml ethanol was added.
1.0 ml of the same stock solution and 0.5 ml of plasma were 
mixed using a Vortex mixer. 2.0 ml of trichloroacetic acid 
(5% w/v) was added and the mixture was centrifuged for 15 minutes.
1.0 ml of supernatant was taken, 1.0 ml OPA and 1.0 ml ethanol 
were added.
3.1.3 Using ethanol as precipitating agent
1.0 ml of gentamicin sulphate solution (0.14 mg/ml) and
0.5 ml of plasma were mixed using a Vortex mixer. 3.0 ml of
ethanol was added and the mixture was centrifuged for 15 minutes.
1.0 ml of supernatant was .'.taken, 1.0 ml OPA reagent and 2.0 ml 
of ethanol were added.
3.1.4 Using methanol as precipitating agent
1.0 ml of gentamicin sulphate solution (0.14 mg/ml) and
0.5 ml of plasma were mixed using a Vortex mixer. 3.0 ml of
methanol was added and the mixture was centrifuged for 15 minutes.
1.0 ml of supernatant was taken, 1.0 ml OPA reagent and 2.0 ml 
of ethanol were added.
3.1.5 Using ammonium sulphate (30% w/v) as precipitating agent
1.0 ml of gentamicin sulphate solution (0.14 mg/ml) and
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0.5 ml of plasma were mixed using a Vortex mixer. 3.0 ml of 
ammonium sulphate was added and the mixture was centrifuged for 
15 minutes. 1.0 ml of supernatant was taken, 1.0 ml OPA reagent 
and 2.0 ml of ethanol were added.
3.1.6 No precipitating agent
1.0 ml of gentamicin sulphate solution (0.14 mg/ml) 
and 0.5 ml of plasma were mixed using a Vortex mixer. 3.0 ml of 
OPA reagent was added and the mixture was centrifuged for 15 minutes.
1.0 ml of supematanb was taken and 3.0 ml of ethanol was added.
3.2 Assay of gentamicin in a plasma sample from a patient
A 38 years old male patient from Royal United Hospital,
Bath, was given gentamicin 120 mg tid. He was also receiving
benzyl peniàillin, erythromycin, frusemide and heparin. 1.0 ml 
of plasma was taken, 0.4 ml of water and 3.0 ml of trichloroacetic 
acid (concentration 5% w/v) were added. The mixture was centfifuged 
for 15 minutes. 1.1.ml of supernatant was taken, 1.0 ml OPA
and 0.9 ml ethanol were added.
5.3 Sulphate assay
Where sufficient commercial gentamicin sulphate sample was 
available, sulphate was assayed titrimetrieally (222).
Preparation of barium perchlorate solution (0.01 M )
Barium perchlorate (3.9 g) was dissolved in 200 ml of de­
ionised water. 800 ml of isopropanol was added.
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Preparation of thorin indicator (0.2%)
Thorin indicator (0.2 g) was dissolved in 100 ml of water.
Standardisation of the barium perchlorate solution
Isopropanol (40 ml) was added to 0.005 M sulphuric acid (20 ml) 
and the pH of the solution adjusted to 2.5 - 4.0 with perchloric 
acid (0.1 N) . Thorin indicator (1 drop) was added and the solution 
was titrated with barium perchlorate solution to the first permanent 
pink.
Titration of the samples
Sample (50 mg) was accurately weighed. De-ionised water (10 
ml) and isopropanol (40 ml) were added and the pH of the solution 
adjusted to 2.5 - 4.0 with perchloric acid (0.1 N). Thorin indicator 
(1 drop) was added and the solution was titrated with barium per­
chlorate to the first permanent pink.
Calculation
-2 -1 
Ba(ClO^)2'3H20 + SO^ ---- > BaSO^ + 2C10^ + SH^O
-2
lOOO ml of 1 M Ba(C10^)2-3H20 = 96 g of SO^
-2
or 1 ml of 0.01 M B a ( C I O ^ ) 3H2O = 0.96 mg of SO^
The percentage of sulphate in a sample can then be calculated from 
the following:
0.96 X volume of barium perchlorate X F x 100 
weight of sample
when F is a factor to adjust the actual concentration of barium
perchlorate solution to O.OlM.
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5.4 Water determination (223)
Sample (0.1 g) was accurately weighed and then dried at 105°C 
until constant weight was obtained.
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Results and Discussion
1. Using fluorescamine derivatives
When mobile phases (1) and (2) were used, each of the 
major components was rapidly eluted with the same retention times 
(30 secs with phase (1) and 1 min with phase (2)1.
When mobile phase (3) was used, the retention time of each 
component was 1.5 minutes but gentamicin and gave two 
additional overlapping peaks.
With mobile phase (4) and (5), all the components gave more 
than one peak. When mobile phase (6) was used, it was found that 
the retention time of each component was more than 30 minutes. 
There was no separation of the gentamicin components.
It has been shown that in the reaction of primary amine 
(gentamicin ) with fluorescamine the end product has a carboxyl 






Thus it was considered that a cationic ion pairing agent might 
achieve a separation. The reagent used was cetyldimethylbenzyl 
ammonium chloride; it was used to prepare mobile phase (7).
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With this system the retention time of each component was
1.7 minutes and there was no separation of gentamicin components. 
Another cation pairing agent, tetrabutyl-ammonium hydroxide, was 
also examined. This was used to prepare mobile phases (8) and (9). 
The retention time was 1.2 minutes for mobile phase (8) and 
longer for mobile phase (9). Again, no separation was obtained.
Since the expected products should also contain underivatised 
secondary amino groups, an anion pairing agent was also examined. 
D-camphor-lO-sulphonic acid (0.01 M) was used in mobile phase (10). 
All the peak heights were greatly reduced. This is probably due 
to the acidic pH of the mobile phase since the optimum pH for 
the fluorescence is between 8 - 10. If the pH of the mobile phase 
is increased the anion pairing agent would occur in its unsuitable 
ionised form. Therefore this reagent is not applicable to this 
case.
The acetonitrile containing systems (mobile phases 11 and 12) 
were also found to reduce the heights of gentamicin peaks and no 
separation was obtained.
The multiple peaks for each component obtained with phases 4-6 
suggested that dérivâtisation may have been incomplete. Accordingly, 
an experiment was performed in which increasing amounts of fluores- 
camine reagent were used.
Figure 65 shows the effect of treating gentamicin with 
increasing amounts of fluorescamine (analysed using phase 4). A
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similar pattern was obtained with the other major components.
Thus it appears that 1 ml of fluorescamine reagent was insufficient 
to completely derivatise the gentamicin and that even with 6 ml 
of fluorescamine reagent more than one product was obtained.
It can be concluded that fluorescamine is not a suitable 
derivatising agent for two reasons:
(1) no separation of the compounds was obtained with any of the 
mobile phases used.
(2) a large excess of reagent was required for complete derivatisation,
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2. U sing 0-phthalaldehyde derivatives
(1) Development of the method
1.1 Reaction conditions
Figures 66, 67, 68, 69, 70 are chromatograms of the 
derivatising agent alone and derivatives of arginine, gentamicin,
gentamicin C^and gentamicin respectively.
It was found that derivatised arginine is not stable to light, 
the peak area declining rapidly with time and giving rise to a 
complex pattern of peaks as shown in Figure 71.
Figure 72 shows that even when stored in the dark the 
arginine derivative undergoes some decomposition but that after 
about 1 hour both the peak area of the arginine derivative and 
the gentamicin/arginine ratio became more stable. The assay 
method utilises this plateau region.
The reaction worked equally well with gentamicin sulphate 
and the base.
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Figure 66.Chromatogram of Figure 67. Chromatogram of
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Figure 73 is a representative chromatogram obtained by this 
method. The elution order for the mixture was arginine, polar 
components, gentamicin gentamicin , gentamicin and
gentamicin C^. It is noteworthy that this order differs from 
that reported by Maitra et al.(172) using a similar HPLC system.
The method of Maitra et al. differs in several details from this 
method.
(1) Maitra et al. carried out the derivatisation reaction with 
the gentamicin adsorbed to silicic gcid. They did not discuss 
the time course of the reaction. Thus it is possible that the 
fluorescent derivatives obtained by these workers were not 
identical to those used in the present study.
(2) Although both studies used a C-18 chemically bonded reverse- 
phase column these were obtained from different manufacturers. 
Several workers, in studies involving polynuclear aromatic hydro­
carbons, steroids and polynuclear aromatic epoxide adducts to 
nucleosides, have observed differences in selectivity in C-18 
chemically bonded stationary phases from different commercial 
sources (224-227).
(3) Maitra e^ al. ran their column at ambient temperature 
whereas in the present method the column was run at 30°C. Since 
increasing temperature reduces carrier viscosity and increases 
diffusion rate, column efficiency can be increased by increasing 
temperature (228). However, it was found that although the use
of an elevated temperature improved resolution it did not alter the 
elution order.
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The specificity of the assay was investigated with respect 
to other aminoglycoside antibiotics, such as neomycin, kanamycin, 
and streptomycin which might be expected to form similar deriva­
tives to gentamicin. Figure 74 shows the chromatograms of 
derivatised neomycin and kanamycin; no peak was observed for 
derivatised streptomycin. Both kanamycin and neomycin elute well 
before any of the major gentamicin peaks but the kanamycin peak 
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Figure 75 shows the calibration graphs for the three major 
gentamicin components.By the use of these graphs the weights of 
gentamicin C^^, C^ and C^ in an unknown can be determined. A 
series of 21 determinations were performed on a single sample 
to give coefficients of variation of 2.64, 2.18 and 1.23% for 













concentration of gentamicin C^, and C^^'(ng)la
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3) Assay of raw materials
A series of 19 commercial samples of gentamicin sulphate from 
various geographical sources, was examined. Where sufficient 
material was available each was assayed for water content by 
loss of weight on drying (223) and for sulphate by titration with 
barium perchlorate (222). The results are shown in Table 19.
Where sufficient material was not available a sulphate content 









SZ-GMC-8—L— 8 31.86 3.76
SZ-GMC-8-L-9 31.58 3.16
Pierrel 061 32.32 3.80
Pierrel 062 32.48 3.74
Pierrel 064 32.96 3.69
Pierrel 065 32.06 4.09
Pierrel 066 31.98 3.86
Pierrel 067 32.83 4.05
B/N °-GMS-8M-6080 33.56 4.57
Figures 76, 77, 78, 79 and 80 show representative 
chromatograms of the gentamicin sulphate mixtures frcxn various 
sources and Table 20 shows the results of the HPLC assay of 
each sample .
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Nicholas 3.75 23.71 37.85 35.25 96.81 4.1
Sample 1 3.82 23.61 35.98 14.64 74.23 2.9
Sample 2 3.82 12.98 41.61 39.76 94.35 0.7
Sample 3 3.82 15.26 45.58 37.24 98.08 1.8
Sample 4 3.82 19.82 50.44 32.06 102.32 2.7
Italian 3.82 15.34 49.99 32.51 97.84 3.3
Hungarian 3.83 17.08 47.99 32.33 97.40 2.1
Chinese 3.82 22.04 39.67 20.27 81.98 4.1
SZ-GMC-8-L-6 3.65 27.77 28.46 25.17 81.40 1.1
SZ~GMC— 8—L—7 3.81 25.38 29.27 26.54 81.19 0.6
SZ—GMC—8—L—8 3.76 24.98 24.73 24.90 74.61 1.9
SZ-GMC-8-L-9 3.16 21.66 28.59 24.65 74.90 0.7
Pierrel 061 3.80 19.09 54.67 16.22 89.98 0.8
Pierrel 062 3.74 19.09 54.84 15.87 89.80 1.3
Pierrel 064 3.69 19.26 55.27 16.01 90.54 0.9
Pierrel 065 4.09 19.16 54.60 16.06 89.82 0.9
Pierrel 066 3.86 19.19 54.38 16.24 89.81 1.7
Pierrel 067 4.05 19.34 55.25 16.26 90.85 0.9
B/N°-GMC-8M-6080^'^^ 26.59 43.37 19.86 89.82 2.1
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It is clear that the component profiles of these samples varied 
more widely than previously reported (164, 151, 163, 160, 161,
107). The geographical origin of the samples seems to be a major 
source of variability. Thus all seven Italian samples are 
characterised by a high gentamicin C ^  content, as is the single 
Hungarian sample. The four Swiss samples (Benzian) all contain 
substantial amounts of gentamicin and another unknown constituent,
Material of Chinese origin also has a high content of minor 
components but a quite different ratio of major components.
These differences may well reflect differences in the strain 
of organism, fermentation conditions, or work up procedure in 
the different manufacturing plants.
(4) Assay of formulations
Seventeen commercially available gentamicin containing 
formulations obtained from three different manufacturers were 
also analysed. Table 21 shows the content of each component 









^la S Cl content
Genticin Injectable 
(Nicholas Lab)
28.72 37.81 39.97 106.5 2.2
Genticin Injectable 
(Nicholas Lab.)
28.42 37.64 34.94 101.0 1.0
Genticin Intrathecal 
(Nicholas Lab.)
25.20 36.54 36.76 98.5 4.1
Genticin Paediatric 
(Nicholas Lab.)
25.66 37.16 39.48 102.3 2.3
Genticin Injectable 
(Nicholas Lab.)
28.89 32.21 38.60 99.7 1.5
Genticin Eye/ear drop 
(Nicholas Lab.)
Gentisone KC
28.68 39.60 40.32 108.6 2.4
ear drops 
(Nicholas Lab.)
33.14 34.35 20.61 97.1 1.0
Genticin cream 
(Nicholas Lab.)
30.34 34.38 35.48 100.2 2.8
Genticin Ointment 
(Nicholas Lab.)
29.72 38.89 35.99 104.6 3.8
Cidomycin Injectable 
(Roussel)
25.74 39.86 38.10 103.7 1.9
Garamycin Injection 
(Warrick)
27.61 37.35 32.04 97.0 3.1
Garamycin Paediatric 
(Warrick)
28.80 36.95 32.55 98.3 0.6
Garamycin Injection 
(Warrick)
29.16 38.22 34.02 101.4 0.4
Amps.Cidomycin Inj  . 
(Roussel)
Cidomycin Injection




28.52 36.85 33.23 98.6 2.0
Intrathecal
(Roussel)
27.83 39.66 44.81 112.3 0.7
Cidomycin Ointment 
(Roussel)
26.43 35.82 36.55 98.8 0.3
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The 'Code of Federal Regulation (1976)' (229) indicates
percentage limits for various preparations.
gentamicin sulphate injection 90 - 125%
gentamicin sulphate ophthalmic dosage form 90 - 135%
gentamicin sulphate ophthalmic ointment 90 - 135%
gentamicin sulphate cream 90 - 135%
It can be seen that all sample formulations assayed by this 
method fell within official limits.
(5) Assay of gentamicin in plasma
Figure 81 compares the chromatogram for gentamicin in plasma 
using trichloroacetic acid as protein precipitating agent with 
those of plasma alone and gentamicin alone.
Table 22 shows peak heights of the gentamicin components 








1. Control 10.60 13.80 8.15 control
2. Trichloroacetic acid 11.45 15.50 8.25 108.1
3. Ethanol 4.65 6.50 4.35 47.6
4. Methanol 7.20 9.45 5.45 67.9
Ammonium sulphate (tube 5) precipitated only a small amount 
of protein and the supernatant was slightly yellow. After deriva- 
tisation and filtration, the solution turned to dark brown and 
was not suitable for injection.
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Figure 81. Chromatogram of gentamicin mixture in plasma.
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When 0-phthalaldehyde was added directly to the plasma (tube 
6 ), the solution remained turbid after centrifugation and fil­
tration and was unsuitable for the injection.
From the above table, it is clear that trichloroacetic acid 
is the best of the protein precipitating agents examined, giving 
approximately 100% recovery. However, the broad peak at the 
start of the chromatogram due to plasma constituents prevents the 
use of arginine as an internal standard. Quantitation was based 
on external standardisation with known concentrations of gentamicin.
With ethanol, only' half of the drug was detected and with 
methanol about 70% of the drug was recovered.
Table 23 shows the percentage recovery of gentamicin at 
various concentrations in the normal therapeutic range when 
trichloroacetic acid was used as protein precipitant.










average percentage recovery 100.0
coefficient of variation 4.99%




Maitra et. • (172) who adsorbed gentamicin from serum onto
silicic acid and derivatised it situ reported that with serum 
concentrations of gentamicin exceeding 2 yg/ml, recovery was 
between 95 - 105%, but with concentrations near 1.0 yg/ml 
the recovery was reduced to 80%.
Figure 82 shows the calibration graphs of gentamicin com­
ponents against concentration which allow the concentration of 
gentamicin in a plasma sample to be read off. One sample obtained 
from a patient contained 9.6 yg/ml. This is within the desired 
therapeutic range. Other drugs (benzyl penicillin, erythromycin 
and frusemide) present in the plasma sample do not contain primary 
amino groups and were not derivatised by 0-phthalaldehyde. They 
did not interfere on the chromatogram.
The present work shows that it is feasible to determine 
gentamicin concentration in plasma using this method. The assay 





























Proton Magnetic Resonance limit test for 
gentamicin
Introduction
The data presented by Calam et al. (154) form the experimental 
basis for the test intended to control the composition of genta­
micin sulphate, and published in the British Pharmacopoeia (1980) 
(185). This was the first exploitation in the British 
Pharmacopoeia of nuclear magnetic resonance spectrometry as an 
analytical technique.
From the NMR spectra of the major components (Figure 83), 
it is clear that gentamicin contains two N-methyl (-NH-CH^) 
groups, one secondary C-methyl group (-CH-CH^) and one tertiary 
C-methyl group (-C-CH^). Gentamicin contains one fewer N- 
methyl groups while gentamicin differs from by the absence 
of the secondary C-methyl group.
These spectra are of gentamicin bases. The sulphates afford 
spectra which are a little less clear because one half of the 
doublet assigned to the secondary C-methyl group is masked by 
the tertiary C-methyl signal (61.36) as illustrated in the 
spectrum of a commercial mixture of gentamicin sulphate (Figure 
84) .
The limit test controls the proportion of the major components 
in commercial gentamicin sulphate mixture by specifying limits for
the ratio of
197,
61.25 (secondary C-methyl) 
61.35 (tertiary C-methyl)
and
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Figure 83. PMR spectrum of gentamicin major components, ppm






Materials and Methods 
Materials
Magnesium sulphate was obtained from B.D.H. Chemicals Limited, 
the reference standard sodium-3-trimethyl silyl propane sulphonate 
(DSS) from the British Oxygen Company Limited, and deuterium oxide 
from Aldrich Chemical Company Limited.
Instrumental settings
Perkin Elmer R12B 60 MHz NMR Spectrometer 
Solvent D^O
Concentration 20% w/v







The proton absorption spectrum of a 20% w/v solution of 
gentamicin in deuterium oxide which had been filtered into a NMR 
table and freed from oxygen by slow bubbling of nitrogen was 
recorded. The frequency reference standard was 0.5% w/v of 
sodium-3-trimethyl silyl propane sulphonate (DSS).
"l' - +
CH. - Si - CH. T- CH„ - CH.-SO- Na 
3 I 2 2 2 3
CH^
201.
The spectrometer controls were adjusted using the peak at 
about 64.75 (DHO peak) given by a 10% w/v solution of magnesium 
sulphate (MgSO^.VH^O) in deuterium oxide as a reference. The phase 
control was adjusted until the instrument was operating in the 
pure absorption mode. The scan speed was set at about 1 Hz per 
second and the filter setting was adjusted such that the noise 
level of the baseline between 60 and 60.5 was in the range 1 to 
3% of full scale deflection. The phase control was further 
adjusted, if necessary, by reference to the mean level of the 
base line between 60.1 and 60.6 and that between 66.1 and 66.6.
The heights of the peaks at about 62.95 (NH-CH^ in all three 
components) and about 61.35 (C-CH^ in all three components were 
recorded at successive radiofrequency settings. The highest 
setting at which the height of the peak at about 62.95 was greater 
than that at about 61.35 was used. The sensitivity control was 
adjusted so that the peak at about 62.95 was as near full scale 
deflection as possible.
The heights of the peaks with chemical shifts of approximately 
61.25, 61.35, 62.75 and 62.95 were measured with respect to a 
baseline drawn between the mean baseline between 60 and 60.5 and 
that between 66.1 and 66.6, and the ratios 61.25/61.35 and 
62.75/62.95 were calculated. The figures quoted in Table 24 are mean 




















Pierrel 061 0.250 0.277
Pierrel 062 0.266 0.294




Pierrel 066 0.274 0.290
Pierrel 067 0.276 0.293
Pierrel 0.251 0.284
B/N°-GMC-8M-6080 U.S.A. 0.260 0.312
The B.P. specifies that the ratio of the height of the peak 
at about 62.75 (NH-CH^ in gentamicin C^) to that of the peak at 
about 62.95 should be between 0.260 and 0.440, and that the ratio 
of the height of the peak at about 61.25 (one peak of the methyl 
doublet for CH-CH^ in gentamicin and C^) to that of the peak 
at about 61.35 should be between 0.200 and 0.260.
All the samples complied with the B.P. specification at 
ratio 62.75/62.95 but 5 samples did not comply at ratio 61.25/61.35
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due to a high content of gentamicin and as indicated by
the CH-CHg signal.
In addition to its use in this limit test the ratio of the 
N-methyl peak at 62.75 to that at 62.95 can be used to estimate 
the gentamicin content of the sample. Thomas (230) has compared 
this method with two chromatographic methods. He suggested that 
because of its speed and simplicity this is the method of choice 
for checking that a sample of gentamicin complies with a defined 
composition, especially when used in conjunction with other 




Gentamicin sulphate is known to consist of a mixture of three 
major components all of which possess antimicrobial activity and 
several minor components, of which the biological activities are 
not well known.
Current official assays for gentamicin sulphate depend primarily 
upon a microbiological estimation of total potency combined with 
other tests to control purity. In the B.P. the ratio of major 
components is controlled within broad limits by means of an NMR test 
whilst the U.S.P. uses paper chromatography followed by a bioauto­
graphic assay.
In the present work an attempt has been made to develop a single 
HPDC assay to measure the amount of each major component and thus 
assess total potency and control purity and component ratios at 
the same time. Table 25 compares the results of HPLC, biological 
assay and NMR limit test applied to 19 samples of commercial 
gentamicin sulphate and Table 26 compares the results of HPLC and 
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Gentamicin injection 101.0 101.3
Gentamicin paediatric 100.2 101.3
Gentamicin Eye/Ear drops 108.6 104.2
Gentamicin/Hydrocortisone 97.1 102.3
Gentamicin ointment 104.6 98.9
Gentamicin Intrathecal 98.5 (a)
(a) This method is not suitable due to the inhibition of 
bacterial growth of saline controls.
It is notable that in the latter case agreement between the 
HPLC method (expressed as the total of major constituents) and the 
biological method is good whereas it is much less good for the 
commercial raw materials. In their assay of gentamicin in plasma 
Maitra £t al. (172) found extremely good correlation between 
their HPLC results and a biological assay.
It is clear that these differences in correlation between the 
two methods depend on the nature of the sanple being analysed. Thus 
Maitra's assay was carried out on plasma from a human volunteer '/ho 
had received a single dose of gentamicin intravenously. All the 
formulations reported in Table 21 contained gentamicin sulphate 
B.P. and the tables show that these varied much less in their HPLC 
profiles than the raw material samples.
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Table 25 shows that whereas the microbiological activities of 
the raw material samples do not differ significantly from each 
other the chemical content of major components does. This implies 
that one or more of the minor components present does possess 
biological activity which contributes to the microbiological 
activity of the mixture. Several workers (107, 158, 104) have 
drawn a similar conclusion from a disparity between chemical and 
biological assays and two minor constituents gentamicin and 
have been isolated (168). However, Thomas and Tappin (151) have 
isolated 3 minor components by ion exchange chromatography which had 
no antimicrobial activity. In this work at least 7 minor components 
have been isolated from a commercial sample of gentamicin (sample 1) 
and have been shown to possess antimicrobial activity. Some of 
these may be identical to compounds of Micromonospora purpurea var. 
nigrescens strain by Bërdy et (166). It is interesting that
sample 1 is in fact one of the purest of those examined.
The precision of both assays is shown by the values of the 
standard deviations. Although 30 replicates were performed in the 
microbiological assay as opposed to 5 in the HPLC assay the 
minimum standard deviation obtained in the biological assay was
I.3 and with most of the samples the values are higher than that 
of the HPLC method.
Table 25 also shows the results of the B.P. NMR limit test 
carried out on commercial samples of gentamicin. Samples 1, 9, 10,
II, 12, 13 and 19 all conplied with the B.P. requirement though 
sample 9 to 12 inclusive (the Swiss samples) all had a relatively 
high content of minor components. Samples 14 to 18 inclusive
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failed to comply due to a high 61.25/61.35 ratio, consistent with
their high proportion of gentamicin C .
2
Thus the broad limits imposed on the gentamicin C component 
ratio by the B.P. NMR limit test will detect and exclude large 
deviations from the 'usual' ratio but seem to be insensitive to the 
presence of minor components. Studies on the biological properties 
of gentamicins C^, and suggest that these compounds differ
only slightly in both antimicrobial activity and toxicity (12).
Thus the observed variations in the major component ratios may be 
of little therapeutic significance whereas the presence of minor 
components of unknown biological activity could be far more 
significant.
It is likely that in the future gentamicin sulphate will 
become available frcxn a wider variety of manufacturing sources 
than at present. Current pharmacopoeial standards are based on 
the restricted sources currently available and it is clear 
that the natural variation in the new sources will lead to some of 
them falling outside the present limits. The methods described in 
this thesis offer a discriminating and flexible means of monitoring 
the composition of gentamicin and hence of providing data upon which 
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